Document:

exv10w47

Exhibit 10.47

FEASIBILITY STUDY, LICENSE AND OPTION AGREEMENT

     This Feasibility Study, License and Option Agreement (this “Agreement”) is made
effective as of August 31, 2008 (the “Effective Date”), by and between Archemix Corp, a
Delaware corporation with offices at 300 Third Street, Cambridge, Massachusetts 02142
(“Archemix”), and Eli Lilly and Company, an Indiana corporation with a business address at
Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Archemix and Lilly are each
sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties.”

     WHEREAS, Archemix is the owner of or otherwise controls, certain patents related to (a) the
identification and optimization of aptamers using its proprietary SELEX Process and SELEX
Technology (each as defined herein) and (b) the use of such aptamers for controlling, curing,
treating, preventing or delaying the onset or progression of human diseases and conditions;

     WHEREAS, Lilly desires to obtain an option to have Archemix conduct a Feasibility Study (as
defined herein) with the objective of demonstrating Archemix’s ability to generate high-affinity
aptamer hits against targets of therapeutic interest to Lilly and, to the extent high-affinity
aptamers are obtained, to obtain an additional option to enter into a collaboration and license
agreement for a specified number of targets; and

     WHEREAS, Archemix is willing to grant Lilly such options and to conduct such Feasibility Study
on the terms and subject to the conditions of this Agreement.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties
hereby agree as follows:

1. DEFINITIONS

     Whenever used in the Agreement with an initial capital letter, the terms defined in this
Article 1 shall have the meanings specified and may be used in singular or plural.

     1.1 “Active Aptamer” means any Aptamer identified in the conduct of the Feasibility
Study or otherwise under this Agreement during the Feasibility Study Term, in any case, that binds
with high specificity and affinity to a Feasibility Study Target and any Aptamer(s) Derived
therefrom that binds with high specificity and affinity to such Feasibility Study Target at a level
to be discussed and agreed upon by the Parties, but typically having dissociation constants in the
range of [***].

     1.2 “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly, controls or is controlled by or is under common control with, such Person. For
purposes of this definition, “control” means (a) ownership of fifty percent (50%) or more of the
shares of stock entitled to vote for the election of directors in the case of a corporation or
fifty percent (50%) or more of the equity interests in the case of any other type of legal entity,
(b) status as a general partner in any partnership, or (c) any other arrangement whereby a Person
controls or has the right to control the board of directors of a corporation or equivalent
governing

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

 

 

body of an entity other than a corporation.

     1.3 “AME Patent Rights” means (a) the patents described in Schedule 1 attached
hereto; (b) any patent application claiming priority to any such patent or to which any such patent
claims priority; (c) any divisional, continuation, continuation-in-part (to the extent that the
continuation-in-part is entitled to the priority date of an initial patent or patent application
which is the subject of this Agreement), reissue, reexamination, confirmation, revalidation,
registration, patent of addition, renewal, extension or substitute thereof, or any patent issuing
therefrom or any supplementary protection certificates related thereto, as well as any certificate
of invention or applications therefrom; and (d) all foreign equivalents of any of the foregoing.

     1.4 “Applicable Laws” means federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, guidance, guidelines or
requirements of regulatory authorities, national securities exchanges or securities listing
organizations, that may be in effect from time to time during the Term and are applicable to a
particular activity hereunder.

     1.5 “Aptamer” means any naturally or non-naturally occurring oligonucleotide
identified through the SELEX Process but excluding Spiegelmers.

     1.6 “Aptamer-Related Patent Rights”means any Patent Rights that contain one or more
claims that cover Aptamer-Related Technology.

     1.7 “Aptamer-Related Technology”means any Feasibility Study Technology that (a)
relates, directly or indirectly, to Aptamers, including  the manufacture, formulation, delivery or
use of Aptamers and (b) is conceived or first reduced to practice by employees of, or consultants
to, Lilly or Archemix, alone or jointly with any Third Party. For purposes of clarity,
Aptamer-Related Technology shall not include any Active Aptamers.

     1.8 “Archemix Background Technology”means any Technology that is used by Archemix, or
provided by Archemix for use, in the Feasibility Study that is (a) Controlled by Archemix as of the
Effective Date or (b) conceived or first reduced to practice by employees of, or consultants to,
Archemix after the Effective Date other than in the conduct of the Feasibility Study. For purposes
of clarity, Archemix Background Technology shall include the SELEX Process and SELEX Technology.

     1.9 “Archemix Collaboration Partner” means any Third Party with whom Archemix is
engaged, from time to time, in an active bona fide collaborative effort to research, identify,
characterize, optimize, develop and/or commercialize Archemix Products, which collaborative effort
is evidenced by a written agreement. For purposes of clarity, as used in this definition, a
“collaborative effort” includes, without limitation, out-licensing of products developed by
Archemix or its Affiliates. Archemix acknowledges and agrees that Archemix is not authorized to
sublicense the Lilly Patent Rights to any third party, except under such a collaboration agreement
and that no Archemix Collaboration Partner may further sublicense, assign or otherwise transfer
rights under the Lilly Patent Rights unless such further sublicense, assignment or other transfer
is limited to the research, identification, characterization, optimization, development and/or
commercialization of Archemix Products that originated from

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

2

 

Archemix or the specific collaborative effort between Archemix and such Third Party.

     1.10 “Archemix Feasibility Study Activities”means all activities specified to be
conducted by Archemix in any Feasibility Study Plan. Without limiting the foregoing, Archemix
Feasibility Study Activities shall include the application of the SELEX Process and SELEX
Technology to generate Active Aptamers against Feasibility Study Targets.

     1.11 “Archemix Feasibility Study Technology”means any Feasibility Study Technology
that is conceived or first reduced to practice by employees of, or consultants to, Archemix, alone
or jointly with any Third Party. For purposes of clarity, Archemix Feasibility Study Technology
shall include all Active Aptamers.

     1.12 “Archemix Field”means any and all uses.

     1.13 “Archemix-Gilead Collaboration Agreement” means the Collaboration Agreement
between Gilead Sciences, Inc. and Archemix dated October 21, 2001, as amended.

     1.14 “Archemix Materials”means any Proprietary Materials that are Controlled by
Archemix and used by Archemix, or provided by Archemix for use, in the Feasibility Study. For
purposes of clarity, Archemix Materials shall include all Aptamers.

     1.15 “Archemix Patent Rights”means any Patent Rights Controlled by Archemix that
contain one or more claims that cover Archemix Technology.

     1.16 “Archemix Portfolio” means those Patent Rights covering the processes used for
the identification or generation of a nucleic acid that binds to a Target by means other than
Watson-Crick base-pairing as set forth in Schedule 3.

     1.17 “Archemix Product”means any product comprised of an Aptamer.

     1.18 “Archemix Technology”means, collectively, Archemix Background Technology and
Archemix Feasibility Study Technology.

     1.19 “Calendar Year” means the period beginning on the Effective Date and ending on
December 31 of the year in which the Effective Date falls and thereafter each successive period of
twelve (12) months commencing on January 1 and ending on December 31.

     1.20 “Challenge” means any challenge to the validity or enforceability of any Archemix
Patent Right or Lilly Patent Right in the absence of a breach of this Agreement including, without
limitation, by (a) filing a declaratory judgment action in which any Archemix Patent Right or Lilly
Patent Right is alleged to be invalid or unenforceable; (b) citing prior art pursuant to [***],
filing a request for re-examination of any Archemix Patent Right or Lilly Patent Rights pursuant to
[***] or provoking or becoming party to an interference with an application for any Archemix Patent
Right or Lilly Patent Right pursuant to [***]; or (c) filing or commencing any reexamination,
opposition, cancellation, nullity or similar proceedings against any Archemix Patent Right or Lilly
Patent Right in any country.

     1.21 “Collaboration Agreement”means the collaboration and license agreement to

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

3

 

be executed by the Parties upon the exercise of any Collaboration/License Option pursuant to
Section 2.5.

     1.22 “Commercially Reasonable Efforts” means, with respect to the activities of
Archemix in conducting the Feasibility Study under this Agreement, the efforts and resources
customarily used by similarly sized biotechnology companies in the performance of such research
activities for other products owned by such companies which are of similar market potential and at
a similar stage of development, taking into account the competitiveness of the market place, the
regulatory structure involved and other relevant and material factors.

     1.23 “Confidential Information” means all information and Technology disclosed or
provided by, or on behalf of a Party (the “Disclosing Party”) to the other Party (the
“Receiving Party”) or to any of the Receiving Party’s employees, consultants, Affiliates or
sublicensees (“Representatives”) pursuant to or in connection with this Agreement;
provided, that, none of the foregoing shall be Confidential Information if: (a) as of the date of
disclosure, it is known to the Receiving Party or its Representatives, as demonstrated by credible
written documentation, other than by virtue of a prior confidential disclosure to such Receiving
Party; (b) as of the date of disclosure it is in the public domain or it subsequently enters the
public domain other than through a breach by the Receiving Party or its Representatives of a
contractual obligation; (c) it is obtained by the Receiving Party from a Third Party having a
lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing
Party or its Representatives; or (d) it is independently developed by or for the Receiving Party or
its Representatives without reference to or use of any Confidential Information of the Disclosing
Party or its Representatives as demonstrated by credible written documentation. For purposes of
clarity, unless excluded from Confidential Information pursuant to the provisos of the preceding
sentence, any scientific, technical or financial information Controlled by a Disclosing Party and
disclosed at any meeting of the Parties shall constitute Confidential Information of the Disclosing
Party.

     1.24 “Control” or “Controlled” means with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without the payment of additional consideration to, and without
violating the terms of any agreement or arrangement with, any Third Party and without violating any
Applicable Laws.

     1.25 “Derived” means directly identified, developed, created, synthesized, designed,
resulting or generated from, conjugated to or complexed with.

     1.26 “Diagnosis” means (a) the determination or monitoring of (i) the presence or
absence of a disease, (ii) the stage, progression or severity of a disease or (iii) the effect on a
disease of a particular treatment; and/or (b) the selection of patients for a particular treatment
with respect to a disease.

     1.27 “Diagnostic Product” means, collectively, In Vitro Diagnostic Agents, In Vivo
Diagnostic Agents and any product used for Diagnosis.

     1.28 “FDA” means the United States Food and Drug Administration and any

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

4

 

successor agency or authority thereto.

     1.29 “Feasibility Study” means the activities carried out by Archemix and Lilly
pursuant to the Feasibility Study Plan.

     1.30 “Feasibility Study Plan”means the written plan describing the activities to be
carried out by Archemix and Lilly in conducting the Feasibility Study pursuant to this Agreement as
set forth in Exhibit A, as such written plan may be amended, modified or updated from
time-to-time.

     1.31 “Feasibility Study Targets” means the Targets listed on the Feasibility Study
Target List.

     1.32 “Feasibility Study Target List”means the list of up to five (5) Feasibility
Study Targets to be identified by Lilly upon exercise of the Feasibility Study Option.

     1.33 “Feasibility Study Technology”means any Technology (including, without
limitation, any new and useful process, method of manufacture or composition of matter) or
Proprietary Materials that are conceived or first reduced to practice (actively or constructively)
by either Party in the conduct of the Feasibility Study during the Feasibility Study Term.

     1.34 “Feasibility Study Term”means, with respect to each Feasibility Study Target,
the period beginning on the acceptance by Archemix of such Feasibility Study Target pursuant to
Section 2.3.4 and ending (a) with respect to any such Feasibility Study Target with regard to which
no Active Aptamer is identified, a period of [***] following the initiation of Archemix Feasibility
Study Activities with respect to such Feasibility Study Target; and (b) with respect to any
Feasibility Study Target with regard to which an Active Aptamer is identified, a period of [***]
following the delivery by Archemix to Lilly of quantities of such Active Aptamer pursuant to
Section 2.4.5; provided, that, if this Agreement is terminated prior to the end of the Feasibility
Study Term, the effective date of such early termination shall become the last day of the
Feasibility Study Term.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

5

 

     1.35 “Field” means the control, prevention, treatment, cure or delay of onset or
progression of any Indication in animals and humans, but excluding, without limitation, Diagnostic
Products, In Vivo Imaging Applications, Radio Therapeutics and all non-therapeutic uses.

     1.36 “Indication” means any indication, disease, disorder or condition in the Field,
which can be treated, controlled, prevented, cured or the onset or progression of which can be
delayed.

     1.37 “In Vitro Diagnostic Agent” means any product that uses the SELEX Process or one
or more Aptamers in the assay, testing or determination, outside of a living organism, of a
substance in a test material. In Vitro Diagnostics shall include, among other things, the use of
the SELEX Process or Aptamers in the assay, testing or determination: (a) outside of a living
organism, (i) of a human substance in a test material, often to identify or follow the progression
of a disease or disorder or to select a patient for treatment; (ii) of a plant substance, animal
substance or other substance in a test material, often to identify or follow the progression of a
disease, process or disorder in a human or non-human organism; and (iii) of environmental
substances (as in water quality testing); (b) of a substance on a test material such as cells (as
in FACS analysis or other measurements of pathogens within biological samples); and (c) any other
in vitro diagnostic use of the SELEX Process or Aptamers in drug development processes, including
target identification, pre-clinical and clinical testing, and the following more specific examples
of uses of Aptamer technology: (i) to observe, through protein profiling, protein levels moving up
or down in diseases or models of diseases, and to evaluate whether such proteins are sensible
targets for the development of therapeutic agents; (ii) to observe coordinated expression of
protein pathways in a variety of biological states in various systems; (iii) to study protein or
metabolite levels during pre-clinical drug candidate evaluation in response to putative therapeutic
agents during clinical trials (e.g., as markers of efficacy or response); and (iv) to study human
protein or metabolite levels in response to putative therapeutic agents during clinical trials
(e.g., as markers of efficacy or response). Notwithstanding the above, In Vitro Diagnostic Agents
do not include any of the above-identified activities directed at the discovery or development of
Aptamers by Lilly under and pursuant to the terms of this Agreement.

     1.38 “In Vivo Diagnostic Agent” means any product containing one or more Aptamers that
is used for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease state.

     1.39 “Joint Patent Rights”means (a) all Patent Rights that contain one or more claims
that cover Joint Technology and (b) all Aptamer-Related Patent Rights.

     1.40 “Joint Technology”means (a) any Feasibility Study Technology that is jointly
conceived or first reduced to practice (actively or constructively) by employees of, or consultants
to, Lilly and employees of, or consultants to, Archemix and (b) all Aptamer-Related Technology.

     1.41 “Kauffman-Ixsys Agreement” means the License Agreement between Stuart A.
Kauffman, M.D. and Ixsys, Inc. dated November 3, 1994, as amended.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

6

 

     1.42 “Knowledge” means, with respect to Archemix, the actual knowledge of the chief
executive officer, any vice president or the chief legal officer of Archemix.

     1.43 “Lilly Feasibility Study Technology”means any Feasibility Study Technology that
(a) is conceived or first reduced to practice by employees of, or consultants to, Lilly, alone or
jointly with any Third Party and (b) is not Aptamer-Related Technology.

     1.44 “Lilly Target Specific Patent Rights”means any Patent Rights Controlled by Lilly
during the Feasibility Study Term that contain one or more claims that cover Lilly Target Specific
Technology.

     1.45 “Lilly Target Specific Technology”means any Technology that is Controlled by
Lilly during the Feasibility Study Term that is necessary or useful for the conduct of the
Feasibility Study involving any Feasibility Study Target.

     1.46 “Lilly Materials”means any Proprietary Materials that are Controlled by Lilly
and provided by Lilly for use in the Feasibility Study. For purposes of clarity, Lilly Materials
shall include all Feasibility Study Targets provided to Archemix for use in the Feasibility Study.

     1.47 “Lilly Patent Rights”means (a) any Patent Rights Controlled by Lilly that
contain one or more claims that cover Lilly Technology and (b) AME Patent Rights.

     1.48 “Lilly Technology”means, collectively, Lilly Feasibility Study Technology and
Lilly Target-Specific Technology.

     1.49 “Patent Rights” means all rights and interests in and to issued patents and
pending patent applications including, without limitation, non-provisional patent applications, and
all divisions, continuations and continuations-in-part thereof, patents issuing on any of the
foregoing, all reissues, reexaminations, renewals and extensions thereof, and supplementary
protection certificates therefor, as well as any certificates of invention or applications
therefor, and all foreign equivalents of any of the foregoing.

     1.50 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a
government.

     1.51 “Radio Therapeutics” means any product for human therapeutic use that contains
one or more Aptamers that targets specifically any diseased tissue, cells or disease-specific
molecules or any tissue or cells which are affected by a disease or located in the close
neighborhood of a disease process and is linked to or incorporates (a) radionucleotides or (b) any
structure or elements which develop therapeutic effects similar to the effect of linking or
incorporating radionucleotides after submission of any kind of radiation.

     1.52 “SELEX Process” means the processes used for the identification or generation of
a nucleic acid that binds to a Target by means other than Watson-Crick base-pairing covered by the
claims in (a) the SELEX Portfolio, (b) the Archemix Portfolio or (c) any continuation,

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

7

 

divisional, continuation-in-part, substitution, renewal, reissue, re-examination or extension,
or any foreign equivalent, of any such claims.

     1.53 “SELEX Portfolio” means those Patent Rights licensed by Gilead to Archemix
pursuant to the Archemix-Gilead Collaboration Agreement set forth in Schedule 4.

     1.54 “SELEX Technology” means (a) oligonucleotides that bind to a Feasibility Study
Target by means other than Watson-Crick base-pairing that consist of or incorporate structural
elements that are generally applicable to such oligonucleotides independent of Feasibility Study
Targets (e.g., a novel nucleoside, bond or linkage or combination(s) thereof, for example,
deoxypurine and 2’O-methyl substituted prymidine compositions) as used in such oligonucleotides,
and (b) any process for modifying, optimizing and/or stabilizing oligonucleotides that bind to a
Feasibility Study Target by means other than Watson-Crick base-pairing that is generally applicable
to such oligonucleotides independent of Feasibility Study Targets wherein such modification,
optimization or stabilization includes, without limitation, minimization, truncation, conjugation,
pegylation, complexation, substitution, deletion and/or incorporation of modified nucleotides;
provided, however, that SELEX Technology does not include Active Aptamers and that the SELEX
Technology is covered by the claims in (a) the SELEX Portfolio, (b) the Archemix Portfolio, or both
or (c) any continuation, divisional, continuation-in-part, substitution, renewal, reissue,
re-examination or extension, or any foreign equivalent, of any such claims.

     1.55 “Spiegelmer”means an oligonucleotide consisting of at least [***] percent
([***]%) [***], including any structural variations and modifications, derivatives, homologs,
analogs and/or mimetics to the [***] components (other than [***]), identified through the use of
the SELEX Process.

     1.56 “Target” means a protein, cytokine, enzyme, receptor, transducer, transcription
factor, antigen or any other non-nucleic acid molecule.

     1.57 “Technology” means, collectively, inventions, discoveries, improvements, trade
secrets and proprietary methods, whether or not patentable, including, without limitation: (a)
methods of production or use of, and structural and functional information pertaining to, chemical
compounds and (b) compositions of matter, data, formulations, processes, techniques, know-how and
results (including any negative results).

     1.58 “Territory” means all countries and jurisdictions of the world.

     1.59 “Third Party” means any person or entity other than Lilly, Archemix and their
respective Affiliates.

     1.60 “ULEHI” means University License Equity Holdings, Inc., formerly known as UTC.

     1.61 “URC Collaboration Agreement” means the Restated Assignment and Collaboration
Agreement, dated July 17, 1991, by and between University Research Corporation and Gilead Sciences,
Inc. as successor in interest to NeXstar Pharmaceuticals, Inc.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

8

 

     1.62 “UTC” means University Technology Corporation, the successor in interest to the
University Research Corporation.

     Additional Definitions. In addition, each of the following definitions shall have the
respective meanings set forth in the section of this Agreement indicated below:

	 	 	 
	Definition	 	Section
	AAA
	 	8.2.1
	Agreement
	 	Recitals
	Archemix
	 	Recitals
	Archemix AME License
	 	2.1.1
	Archemix Claims
	 	6.1
	Archemix Indemnitees
	 	6.1
	Bankruptcy Action
	 	7.2.4
	Collaboration Agreement
	 	2.5.2(a)
	Collaboration/License Negotiation Period
	 	2.5.2(a)
	Collaboration/License Option
	 	2.5.1
	Collaboration/License Option Exercise Notice
	 	2.5.2(a)
	Collaboration/License Option Period
	 	2.5.2(a)
	Disclosing Party
	 	1.22
	Effective Date
	 	Recitals
	Exclusive Feasibility Study Target
	 	2.3.2
	Exclusive Feasibility Study Target Notice
	 	2.3.2
	Expired Collaboration/License Option
	 	2.5.3
	Feasibility Study License
	 	2.1.1
	Feasibility Study Option
	 	2.2.1
	Feasibility Study Option Exercise Notice
	 	2.2.2
	Feasibility Study Option Period
	 	2.2.2
	Feasibility Study Target Notice
	 	2.3.1
	Gilead Indemnitee
	 	6.4
	Indemnified Party
	 	6.3
	Indemnifying Party
	 	6.3
	Infringement
	 	4.5.1
	Infringement Notice
	 	4.5.1
	Lilly
	 	Recitals
	Lilly Claims
	 	6.2
	Lilly Indemnities
	 	6.2
	Negotiation Dispute
	 	2.5.2
	Party
	 	Recitals
	Parties
	 	Recitals
	Receiving Party
	 	1.22
	Recipient Party
	 	2.4.6
	Representatives
	 	1.22
	Term
	 	7.1
	Third Party Expert
	 	8.2.2(a)
	Transferring Party
	 	2.4.6

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

9

 

2. GRANT OF RIGHTS

     2.1 Grant of Licenses to Archemix.

          2.1.1 Grant of Licenses. Subject to the other terms and conditions of this Agreement
and in consideration of the grant by Archemix to Lilly of the rights set forth in Sections 2.2 and
2.5, Lilly hereby grants to Archemix (a) a non-exclusive, royalty-free, fully paid-up license
during the Feasibility Study Term, without the right to grant sublicenses, under all Lilly Target
Specific Technology and Lilly Target Specific Patent Rights to conduct the Feasibility Study with
the Feasibility Study Targets that are identified in a Feasibility Study Option Exercise Notice
(the “Feasibility Study License”) and (b) a non-exclusive, royalty-free, fully paid-up,
perpetual, irrevocable (except in the event of termination by Lilly under Section 7.2.3 during the
Feasibility Study Term when such license shall be revocable for material breach or as extended
during the Collaboration/License Negotiation Period under Section 2.5.2(a), if applicable),
worldwide license, with the right to grant sublicenses to Archemix Collaboration Partners, under
AME Patent Rights, to research, develop, make, have made, use, have used, sell, offer for sale,
have sold, import, have imported, export, have exported, and commercialize Archemix Products within
the Archemix Field (the “Archemix AME License”).

     2.2 Grant of Feasibility Study Option to Lilly.

          2.2.1 Feasibility Study Option Grant. Archemix hereby grants Lilly an option (the
“Feasibility Study Option”) to have Archemix conduct the Feasibility Study for the purpose
of having Archemix demonstrate its ability to generate Active Aptamers against Feasibility Study
Targets.

          2.2.2 Feasibility Study Option Exercise. Subject to Section 2.2.3, Lilly shall have
the right to exercise the Feasibility Study Option at any time during the period commencing on the
Effective Date and continuing until [***] (the “Feasibility Study Option Period”), by
delivering written notice of exercise thereof (the “Feasibility Study Option Exercise
Notice”) on or before the expiration of the Feasibility Study Option Period, which Feasibility
Study Option Exercise Notice shall include the Feasibility Study Target Notice. Upon the exercise
by Lilly of the Feasibility Study Option, (a) Lilly shall be deemed to have granted Archemix the
Feasibility Study License set forth in Section 2.1.1(a) and (b) Archemix shall commence the
Feasibility Study with respect to the Feasibility Study Targets identified in the Feasibility Study
Option Exercise Notice within [***] of the date of such exercise; provided, that, (i) Lilly has
provided Archemix with the materials and resources as set forth in Section 2.4.2 and (ii)
notwithstanding the foregoing, Archemix shall not be required to initiate the Feasibility Study
prior to [***].

          2.2.3 Feasibility Study Option Expiration. In the event that Lilly fails to (a)
exercise the Feasibility Study Option on or before the expiration of the Feasibility Study Option
Period, or (b) provide the materials and resources required by Section 2.4.2 on a timely basis
following the exercise by Lilly of the Feasibility Study Option, all rights granted by Archemix to
Lilly pursuant to this Agreement with respect to the Feasibility Study Option shall terminate at
Archemix’s sole discretion and upon notice to Lilly.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

10

 

     2.3 Designation of Feasibility Study Targets.

          2.3.1 Designation of Feasibility Study Targets. Subject to Sections 2.3.3, 2.3.4 and
2.3.5, during the period commencing on the Effective Date and continuing until the expiration of
the Feasibility Study Option Period, Lilly shall have the one-time right to request that up to
[***] Targets be accepted by Archemix as Feasibility Study Targets and included on the Feasibility
Study Target List by providing written notice to Archemix, which notice shall identify each such
proposed Feasibility Study Target (each, a “Feasibility Study Target Notice”). Archemix
shall determine whether to accept or reject any such proposed Feasibility Study Target pursuant to
Section 2.3.4. To the extent Archemix accepts any Target for inclusion as a Feasibility Study
Target on the Feasibility Study Target List in accordance with Section 2.3.4 such Target shall be
included as a Feasibility Study Target. To the extent that Archemix rejects any Target for
inclusion as a Feasibility Study Target on the Feasibility Study Target List in accordance with
Section 2.3.4 Lilly shall have no rights under this Agreement with respect to such Target.

          2.3.2 Designation of Exclusive Feasibility Study Targets. Subject to Sections 2.3.3,
2.3.4 and 2.3.5, during the period commencing on Archemix’s receipt of the Feasibility Study Option
Exercise Notice and Feasibility Study Target Notice and continuing until the expiration of the
Feasibility Study Term, Lilly shall have the right to request that up to two (2) Feasibility Study
Targets be accepted by Archemix as exclusive Feasibility Study Targets (each, an “Exclusive
Feasibility Study Target”) and designated on the Feasibility Study Target List as Exclusive
Feasibility Study Targets by providing written notice to Archemix, which notice shall identify each
such proposed Exclusive Feasibility Study Target (each, an “Exclusive Feasibility Study Target
Notice”). To the extent Archemix accepts any Feasibility Study Target for designation as an
Exclusive Feasibility Study Target on the Feasibility Study Target List in accordance with Section
2.3.4 during the Feasibility Study Term, Archemix shall not, and shall cause each of its Affiliates
to not, conduct any activity, that involves the research, development or commercialization of, or
grant any license or other rights to any Archemix Collaboration Partner under any Proprietary
Materials, Technology or Patent Rights Controlled by Archemix or any of its Affiliates to research,
develop or commercialize, any Aptamer binding to such Exclusive Feasibility Study Target in the
Field. To the extent that Archemix rejects any Target for designation as an Exclusive Feasibility
Study Target on the Feasibility Study Target List in accordance with Section 2.3.4, such
Feasibility Study Target will remain a Feasibility Study Target and Lilly shall have no exclusive
rights under this Agreement with respect to such Feasibility Study Target. For purposes of
clarity, Lilly shall have no rights under this Agreement with respect to any Target unless and
until such Target is proposed by Lilly pursuant to Section 2.3.1 and accepted by Archemix as a
Feasibility Study Target pursuant to Section 2.3.4.

          2.3.3 Selection of Proposed Targets. Lilly hereby agrees that it shall propose
Targets for inclusion as Feasibility Study Targets only after reasonable consultation and
discussion with Archemix and only after consideration by Lilly of the technical feasibility and
availability of such Targets.

          2.3.4 Acceptance/Rejection of Feasibility Study Targets by Archemix. To the extent
Lilly requests the inclusion of a Target as a Feasibility Study Target pursuant to Sections 2.3.1
or the designation of a Feasibility Study Target as an Exclusive Feasibility Study Target

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

11

 

pursuant to Section 2.3.2, Archemix shall accept or reject the proposed Target within [***]
days after receipt of such notice from Lilly. A Target proposed by Lilly for inclusion on the
Feasibility Study Target List or for designation as an Exclusive Feasibility Study Target on the
Feasibility Study Target List may only be rejected by Archemix if prior to Lilly’s notice (a)
Archemix is prohibited by an executed contract from licensing Aptamers against such proposed Target
or its natural ligand(s), to Lilly, (b) Archemix is in active negotiations, as demonstrated by
written term sheets with a Third Party with respect to a license, collaboration or similar
agreement relating to Aptamers against such Target or its natural ligand(s), (c) Archemix is
developing, for its own benefit, Aptamers against such Target or its natural ligand(s) under a bona
fide internal development program against such Target, has adopted a research plan for such Target
or its natural ligand, or has formally designated such Target or its natural ligand(s) for research
or (d) Archemix has identified such Target as a cardiovascular or hematologic Target of strategic
interest to Archemix, in each of (c) and (d) as demonstrated by credible written evidence. If
Lilly requests the inclusion of [***] or more Targets as Feasibility Study Targets pursuant to
Section 2.3.1 or the designation of two (2) or more Feasibility Study Targets as Exclusive
Feasibility Study Targets pursuant to Section 2.3.2 and Archemix accepts less than [***] such
Feasibility Study Targets and/or less than two (2) Exclusive Feasibility Study Targets pursuant to
this Section 2.3.4, Lilly shall have up to [***] additional periods of [***] days each, each such
period to begin upon receipt of the applicable notice from Archemix rejecting or accepting proposed
Targets, to request that additional Targets be included as Feasibility Study Targets pursuant to
Section 2.3.1 or additional Feasibility Study Targets be designated as Exclusive Feasibility Study
Targets pursuant to Section 2.3.2, subject in either case to Section 2.3.5, until such time as
[***] Feasibility Study Targets and two (2) Exclusive Feasibility Study Targets have been accepted
by Archemix pursuant to this Section 2.3.4.

          2.3.5 Limitation on Number of Feasibility Study Targets and Exclusive Feasibility Study
Targets. Notwithstanding anything to the contrary in this Agreement, under no circumstances
shall Lilly have, at any one time, (a) more than [***] Feasibility Study Targets on the Feasibility
Study Target List nor (b) more than two (2) Exclusive Feasibility Study Targets on the Feasibility
Study Target List.

     2.4 Conduct of Feasibility Study.

          2.4.1 Archemix Responsibilities. Commencing as of the date of exercise of the
Feasibility Study Option, Archemix shall use Commercially Reasonable Efforts, including committing
such resources as are reasonably necessary for Archemix to conduct the Feasibility Study described
in the Feasibility Study Plan, to conduct the Archemix Feasibility Study Activities and complete
its obligations set forth in the Feasibility Study Plan on or before [***] months from the
initiation of such Feasibility Study; provided, that, notwithstanding the foregoing, (a) all
Archemix Feasibility Study Activities with respect to Feasibility Study Targets shall be initiated
by Archemix on the same date and (b) no Feasibility Study Targets may be proposed by Lilly after
the initiation by Archemix of such Archemix Feasibility Study Activities

          2.4.2 Lilly Rights and Responsibilities. Upon exercise of the Feasibility Study
Option, Lilly shall: (a) provide Archemix with the sufficient quantities of each Feasibility Study
Target set forth in the applicable Feasibility Study Option Exercise Notice within [***] months of
the delivery by Lilly of such Feasibility Study Option Exercise Notice and acceptance by Archemix
of the Feasibility Study Targets and in sufficient form for the conduct of the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

12

 

Feasibility Study; (b) commit such resources as are reasonably necessary for Archemix to
conduct the Feasibility Study described in the Feasibility Study Plan; and (c) as soon as
practicable conduct in vitro functional assays with respect to all Active Aptamers supplied by
Archemix pursuant to Section 2.4.5 until expiration of the Feasibility Study Term. In connection
therewith, Lilly hereby agrees to use such Active Aptamers solely to conduct in vitro functional
assays covering such Active Aptamers and for no other use or purpose and hereby acknowledges that
all such Active Aptamers shall be Proprietary Materials of Archemix and subject to Section 2.4.6.

          2.4.3 Compliance. Archemix shall perform its obligations under the Feasibility Study
Plan in compliance in all material respects with all Applicable Laws.

          2.4.4 Reports. Archemix shall at least [***] each Calendar Quarter during the
Feasibility Study Term, provide reports to Lilly in reasonable detail regarding the status of its
activities under the Feasibility Study. Archemix shall make itself available at reasonable times
to provide Lilly with telephonic, email and other updates as Lilly reasonably requests.

          2.4.5 Supply of Active Aptamers by Archemix. To the extent that Archemix identifies
Active Aptamers in the conduct of the Feasibility Study, Archemix shall, as soon as practicable
following the issuance of the report identifying such Active Aptamers, supply Lilly with a quantity
of such Active Aptamer sufficient for Lilly to conduct in vitro functional assays covering such
Active Aptamer.

          2.4.6 Supply of Proprietary Materials. To the extent that either Party (the
“Transferring Party”) supplies the other Party (the “Recipient Party”) with
Proprietary Materials of the Transferring Party for use in the Feasibility Study, each Recipient
Party hereby agrees that (a) it shall not use such Proprietary Materials for any purpose other than
exercising its rights or performing its obligations under this Agreement; (b) it shall use such
Proprietary Materials only in compliance with all Applicable Laws; (c) it shall not transfer any
such Proprietary Materials to any Third Party without the prior written consent of the Transferring
Party, except as expressly permitted by this Agreement; provided, however, that Lilly may transfer
such Proprietary Materials under a material transfer agreement or equivalent agreement to (x) bona
fide collaborators as part of a research collaboration where work is being done primarily for
Lilly’s benefit and (y) contractors for services related to the Proprietary Materials; provided
further, however, that each such agreement under (x) and (y) states that the Proprietary Materials
may not be transferred to another Third Party and are otherwise subject to the other terms and
conditions of this Agreement to the benefit of Archemix; (d) the Recipient Party shall not acquire
any right, title or interest in or to such Proprietary Materials as a result of such supply by the
Transferring Party; and (e) upon the expiration or termination of the Feasibility Study Term, the
Recipient Party shall, if and as instructed by the Transferring Party, either destroy or return any
such Proprietary Materials that are not the subject of the grant of a continuing license hereunder.

          2.4.7 Feasibility Study Term. The Feasibility Study shall commence on the first day
of the Feasibility Study Term and shall continue until the last to expire Feasibility Study Term.

     2.5 Grant of Collaboration/License Option to Lilly.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

13

 

          2.5.1 Grant of Collaboration/License Option. Archemix hereby grants Lilly, with
respect to each Feasibility Study Target, an option (each a “Collaboration/License Option”)
to enter into a collaboration and exclusive license agreement in the Territory under Archemix
Patent Rights and Archemix Technology with respect to up to [***] Feasibility Study Targets for the
purpose of researching, developing, making, having made, using, having used, selling, having sold,
offering for sale, importing, having imported, exporting and having exported Active Aptamers
directed to such Feasibility Study Targets for any and all uses within the Field. For purposes of
clarity, Collaboration/License Options shall only be available with respect to Feasibility Study
Targets that are listed on the Feasibility Study Target List.

          2.5.2 Collaboration/License Option Exercise; Negative Covenants.

               (a) Collaboration/License Option. Subject to Section 2.5.3, Lilly shall have the
right to exercise each Collaboration/License Option at any time during the Feasibility Study Term
(the “Collaboration/License Option Period”) by delivering written notice of exercise
thereof (the “Collaboration/License Option Exercise Notice”) on or before the expiration of
the Collaboration/License Option Period, which Collaboration/License Option Exercise Notice shall
specify the Feasibility Study Target that is the subject of the Collaboration/License Option. Upon
the exercise of a Collaboration/License Option with respect to a Feasibility Study Target as
provided in this Section 2.5.2, the Parties shall negotiate in good faith a separate Collaboration
and License Agreement (each, a “Collaboration Agreement”) covering such Feasibility Study
Target for a period of up to [***] months (the “Collaboration/License Negotiation Period”),
which Collaboration Agreement shall include the terms, conditions and provisions set forth in
Schedule 2 attached hereto and such additional provisions as are usual and customary for
inclusion in a collaboration and license agreement between companies in the pharmaceutical industry
of comparable sizes to the respective Parties. For purposes of clarity, such additional terms
shall supplement and shall not materially expand, limit or change the terms set forth on
Schedule 2. In the event that, notwithstanding such good faith efforts, the Parties fail
to execute and deliver the Collaboration Agreement within the Collaboration/License Negotiation
Period, the Parties shall (a) use reasonable efforts to complete such negotiations and to execute
and deliver the Collaboration Agreement as soon as possible after such Collaboration/License
Negotiation Period, and (b) without limiting the generality of the foregoing, after the expiration
of such additional period, each produce a list of issues not otherwise set forth on Schedule
2 on which they have failed to reach agreement and submit its list to the Third Party Expert to
be resolved in accordance with Section 8.2.2 (a “Negotiation Dispute”).

               (b) Negative Covenants. Notwithstanding anything to the contrary in this Agreement,
Lilly shall not be granted the right in any Collaboration Agreement to, and hereby covenants and
agrees that neither it nor its Affiliates will under any such Collaboration Agreement (i) use the
SELEX Process or SELEX Technology (A) on any Target that is not the Feasibility Study Target that
is the subject of the Collaboration Agreement and (B) except for the purpose of identifying or
modifying Active Aptamers against the Feasibility Study Target that is the subject of the
Collaboration Agreement as expressly permitted under the Collaboration Agreement, (ii) research,
develop, make, have made, use, have used, sell, offer for sale, have sold, distribute for sale,
import, have imported, export or have exported Diagnostic Product or (iii) perform any research or
development on Active Aptamers for any use outside of the Field. Notwithstanding the foregoing,
Lilly shall not be restricted by this Section 2.5.2(b) from engaging

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

14

 

in any activity in which Lilly is permitted to engage pursuant to a license, sublicense or
other right granted to Lilly in any agreement other than the Collaboration Agreement with respect
to the SELEX Portfolio, the SELEX Process, SELEX Technology or Aptamers, whether granted by
Archemix, or any Third Party having the right to grant such license, sublicense or other right. To
the extent Lilly or its Affiliates engages in any activities in violation of the negative covenants
set forth in this Section 2.5.2(b) during the term of the Collaboration Agreement and files any
patent applications or obtains any Patent Rights related to or arising out of such activities then,
without limiting any other remedy Archemix may have under this Agreement and without any further
action of either Party, if Lilly has willfully undertaken such activities, then Lilly shall be
deemed to have granted to Archemix, effective as of the date of any such filing, or the date on
which such Patent Rights are obtained, an exclusive, fully-paid, perpetual, irrevocable,
royalty-free license under all such patent applications and Patent Rights for any and all uses; if
Lilly has not willfully undertaken such activities (i.e., it is not culpable), then Lilly shall be
deemed to have granted to Archemix, effective as of the date of any such filing, or the date on
which such Patent Rights are obtained, a non-exclusive, fully-paid, perpetual, irrevocable,
royalty-free license under all such patent applications and Patent Rights for any and all uses.

          2.5.3 Option Expiration. In the event that Lilly fails to exercise any
Collaboration/License Option on or before the expiration of the Collaboration/License Option Period
(each, an “Expired Collaboration/License Option”), (a) all rights granted by Archemix to
Lilly pursuant to this Agreement with respect to each such Expired Collaboration/License Option
shall terminate and (b) Archemix shall promptly return to Lilly all Lilly Materials provided to
Archemix and not otherwise the subject of a Collaboration Agreement.

3. TREATMENT OF CONFIDENTIAL INFORMATION

     3.1 Confidentiality Obligations. Archemix and Lilly each recognizes that the other
Party’s Confidential Information constitutes highly valuable assets of such other Party. Archemix
and Lilly each agrees that, subject to the remainder of this Article 3, it will hold in confidence
and will not disclose, and will cause its Affiliates and sublicensees not to disclose, any
Confidential Information of the other Party and it will not use, and will cause its Affiliates and
sublicensees not to use, any Confidential Information of the other Party except as expressly
permitted hereunder; provided, that, such obligations shall apply during the Term and for an
additional [***] years thereafter.

     3.2 Limited Disclosure and Use. Archemix and Lilly each agrees that disclosure of its
Confidential Information may be made by the other Party to any employee, consultant, contractor or
Affiliate of such other Party to enable such other Party to exercise its rights or to carry out its
responsibilities under this Agreement; provided, that, any such disclosure or transfer shall only
be made to Persons who are bound by written obligations as described in Section 3.3. In addition,
Archemix and Lilly each agrees that the other Party may disclose its Confidential Information (a)
on a need-to-know basis to such other Party’s legal and financial advisors, (b) as reasonably
necessary in connection with an actual or potential (i) permitted sublicense of such other Party’s
rights hereunder, (ii) debt or equity financing of such other Party or (iii) transfer or sale of
all or substantially all of such Party’s assets or business or in the event of its merger,
consolidation, change in control or similar transaction, and (c) for any other purpose with the
other Party’s written consent, not to be unreasonably withheld, conditioned or delayed. In

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

15

 

addition, each Party agrees that the other Party may disclose such Party’s Confidential
Information as required by Applicable Laws; provided, that, in the case of any such disclosure, the
disclosing Party shall (i) if practicable, provide the other Party with reasonable advance notice
of and an opportunity to comment on any such required disclosure and (ii) if requested by the other
Party, cooperate in all reasonable respects with the other Party’s efforts to obtain confidential
treatment or a protective order with respect to any such disclosure, at the other Party’s expense.

     3.3 Employees and Consultants. Lilly and Archemix each hereby represents that all of
its employees, consultants and contractors, and all of the employees, consultants and contractors
of its Affiliates, who have access to Confidential Information of the other Party are or will,
prior to their participation or access, be bound by written obligations to maintain such
Confidential Information in confidence and not to use such information except as expressly
permitted hereunder. Each Party agrees to use, and to cause its Affiliates to use, reasonable
efforts to enforce such obligations.

     3.4 Publicity. The Parties acknowledge and agree that (a) the terms of this Agreement
constitute Confidential Information of each Party and may only be disclosed (i) as permitted by
Section 3.2, and (ii) to investment bankers, investors, and potential investors, lenders and
potential lenders and other sources and other potential sources of financing, licensees and
potential licensees, acquirers or merger partners and potential acquirers or merger partners of
such Party, and, with respect to Archemix, to Gilead and University License Equity Holdings, Inc.;
and (b) a copy of this Agreement may be filed by either Party with the Securities and Exchange
Commission if such filing is required by Applicable Laws; provided, that, in connection with any
such filing, such Party shall endeavor to obtain confidential treatment of economic and trade
secret information, and shall provide the other Party with the proposed confidential treatment
request with reasonable time for such other Party to provide comments, which comments shall be
reasonably considered by the filing Party. Notwithstanding anything to the contrary in Section
3.1, except as required by Applicable Laws, neither Party shall issue a press or news release or
make any similar public announcement related to this Agreement without the prior written consent of
the other Party.

4. INTELLECTUAL PROPERTY RIGHTS AND PROVISIONS

     4.1 Archemix Patent Rights. Archemix shall have sole and exclusive ownership of all
right, title and interest on a worldwide basis in and to any Archemix Patent Rights.

     4.2 Lilly Patent Rights. Lilly shall have sole and exclusive ownership of all right,
title and interest on a worldwide basis in and to any and all Lilly Patent Rights.

     4.3 Joint Technology; Joint Patent Rights. Lilly and Archemix shall jointly own all
Joint Technology and Joint Patent Rights. Notwithstanding anything to the contrary contained in
this Agreement or under Applicable Laws, except to the extent exclusively licensed to one Party
under this Agreement, the Parties hereby agree that either Party may use or license or sublicense
to Affiliates or Third Parties all or any portion of its interest in Joint Technology, Joint Patent
Rights or jointly owned Confidential Information for any purposes without the prior written consent
of the other Party, without restriction and without the obligation to provide

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

16

 

compensation to the other Party, except as otherwise provided under this Agreement, provided,
that, to the extent that any Joint Technology and/or Joint Patent Rights are necessary or useful
for the research, development, manufacture, use, sale, importation or exportation of an Active
Aptamer being commercialized by Lilly pursuant to an executed Collaboration Agreement, Archemix
shall not use or license to a Third Party its interest in such Joint Technology and/or Joint Patent
Rights to develop or commercialize any Aptamers that were selected against and bind to the
applicable Feasibility Study Target.

     4.4 Prosecution of Patent Rights.

          4.4.1 Archemix Patent Rights. Archemix, at its sole expense and acting through patent
counsel or agents of its choice, shall be solely responsible for the preparation, filing,
prosecution and maintenance of the Archemix Patent Rights.

          4.4.2 Lilly and AME Patent Rights. Lilly and/or its Affiliates, as applicable, at its
sole expense and acting through patent counsel or agents of its choice, shall have the sole
responsibility and obligation for the preparation, filing, prosecution and maintenance of the Lilly
Patent Rights.

          4.4.3 Joint Patent Rights. Archemix acting through patent counsel or agents of its
choice, shall be responsible, at its own expense, for the preparation, filing, prosecution and
maintenance of all Joint Patent Rights. Archemix shall provide Lilly and its patent counsel with an
opportunity to consult with Archemix and its patent counsel regarding the filing and contents of
any application, amendment, submission or response filed pursuant to this Section 4.4.3. Archemix
shall (a) regularly provide Lilly with copies of all patent applications filed hereunder for Joint
Patent Rights and other material submissions and correspondence with the patent offices, in
sufficient time to allow for review and comment by Lilly; and (b) provide Lilly and its patent
counsel with an opportunity to consult with Archemix and its patent counsel regarding the filing
and contents of any such application, amendment, submission or response, and the advice and
suggestions of Lilly and its patent counsel shall be taken into consideration in good faith by
Archemix and its patent counsel in connection with such filing. Archemix shall pursue in good
faith all reasonable claims and take such other reasonable actions, as may be requested by Lilly in
the prosecution of any Joint Patent Rights under this Section 4.4.3; provided, however, if Archemix
incurs any additional expense as a result of any such request, Lilly shall be responsible for the
cost and expenses of pursuing any such additional claim or taking such other activities.

     4.5 Infringement.

          4.5.1 Notice. In the event that during the Term either Party becomes aware of any
possible infringement of any Archemix Patent Rights, Lilly Patent Rights or Joint Patent Rights,
including the submission by any Third Party of an abbreviated new drug application under the
Hatch-Waxman Act or its equivalent outside the United States for a generic product (each, an
“Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”).

          4.5.2 Infringement of Archemix Patent Rights. Archemix shall have the sole right, but
not the obligation, in its sole discretion, at its own expense and with legal counsel of its own
choice, to bring suit (or take other appropriate legal action) against any actual, alleged or

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

17

 

threatened Infringement of the Archemix Patent Rights.

          4.5.3 Infringement of Lilly Patent Rights. Lilly shall have the first right, but not
the obligation, at its own expense and with legal counsel of its own choice, to bring suit (or take
other appropriate legal action) against any actual, alleged or threatened Infringement of the Lilly
Patent Rights. Archemix shall have the right, at its own expense, to be represented in any such
action by Lilly that involves the assertion of the AME Patent Rights regarding an Infringement
relating to Aptamers or the SELEX Process by counsel of Archemix’s own choice; provided, that,
under no circumstances shall the foregoing affect the right of Lilly to control the suit as
described in the first sentence of this Section 4.5.3.

          4.5.4 Infringement of Joint Patent Rights. In the event of an Infringement of a Joint
Patent Right, the Parties shall enter into good faith discussions as to whether and how to
eliminate the Infringement. Each Party shall bear [***] of the cost of any action, suit or
proceeding instituted under this Section 4.5.4 and [***] of all amounts recovered shall be received
by each Party; provided, that, if the Parties are unable to determine whether and how to institute
an action, suit or proceeding for Infringement of any such Joint Patent Right, Archemix shall have
the first right to prosecute such Infringement, in which event Archemix shall bear [***] and be
entitled to retain [***]. Each Party shall have the right to be represented by counsel of its own
selection in any action, suit or proceeding instituted under this Section 4.5.4 by the other Party.
If a Party lacks standing and the other Party has standing to bring any such action, suit or
proceeding, then the Party with standing shall bring such suit at the request and expense of the
other Party.

5. REPRESENTATIONS AND WARRANTIES

     5.1 Mutual Representations and Warranties. Archemix and Lilly each represents and
warrants to the other, as of the Effective Date, as follows:

          5.1.1 Organization. It is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, and has all requisite power and
authority, corporate or otherwise, to execute, deliver and perform this Agreement.

          5.1.2 Authorization. The execution and delivery of this Agreement and the performance
by it of the transactions contemplated hereby have been duly authorized by all necessary corporate
action and will not violate (a) such Party’s certificate of incorporation or bylaws, (b) any
agreement, instrument or contractual obligation to which such Party is bound in any material
respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment, injunction,
decree, determination or award of any court or governmental agency presently in effect applicable
to such Party.

          5.1.3 Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party enforceable against it in accordance with its terms and conditions.

          5.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

18

 

     5.2 Acknowledgment of Lilly. Lilly acknowledges that the licenses and rights that may
be granted to Lilly under an executed Collaboration Agreement are subject to certain limitations
and restrictions set forth in the Archemix-Gilead Collaboration Agreement and agrees that Lilly
shall be required in any such Collaboration Agreement to comply with the terms of the
Archemix-Gilead Collaboration Agreement that Archemix is subject to thereunder.

     5.3 Acknowledgment of Archemix. Archemix acknowledges that the licenses and rights
that may be granted to Archemix under this Agreement are subject to certain limitations and
restrictions set forth in the Kauffman-Ixsys License Agreement and agrees that Archemix shall
comply with the terms of the Kauffman-Ixsys Agreement that Lilly is subject to thereunder.

     5.4  Additional Representations and Warranties.

          5.4.1  Additional Representations and Warranties of Archemix.

               (a) Authority. Archemix represents and warrants to Lilly that Archemix Controls the
Archemix Patent Rights and has the right to grant the rights granted to Lilly on the terms set
forth herein.

               (b) No Litigation. Archemix represents and warrants to Lilly that, as of the
Effective Date and with no further duty to update, to Archemix’s Knowledge, there is no pending
litigation against Archemix that seeks to invalidate or oppose any of the patents or patent
applications included in the Archemix Patent Rights.

               (c) No Infringement. Archemix represents and warrants to Lilly that to its Knowledge,
there is no litigation pending or threatened that alleges that (i) the practice of the SELEX
Process and/or the use of SELEX Technology as contemplated by this Agreement infringes the Patent
Rights of any Third Party, (ii) the Archemix Patent Rights are invalid or unenforceable; or (iii)
the use of the Archemix Patent Rights as contemplated by this Agreement infringes the Patent Rights
of any Third Party.

          5.4.2 Additional Representations and Warranties of Lilly.

               (a) Authority. Lilly represents and warrants to Archemix that Lilly Controls the
Lilly Patent Rights and the AME Patent Rights and has the right to grant the Feasibility Study
License and the Archemix AME License granted to Archemix on the terms set forth herein.

               (b) No Litigation. Lilly represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update, there is no pending litigation against Lilly or
any Affiliate of Lilly that seeks to invalidate or oppose any of the patents or patent applications
included in the AME Patent Rights.

6. INDEMNIFICATION AND INSURANCE

     6.1 Indemnification of Archemix by Lilly. Lilly shall indemnify, defend and hold
harmless Archemix, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “Archemix Indemnitees”), against any
liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of
litigation) incurred by or imposed upon the Archemix Indemnitees, or any one of them, as a direct
result of

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

19

 

claims, suits, actions or demands by Third Parties (collectively, the “Archemix
Claims”) arising out of (a) Lilly’s research of any Active Aptamer or (b) the gross negligence
or willful misconduct of Lilly or any of its Affiliates.

     6.2 Indemnification of Lilly by Archemix. Archemix shall indemnify, defend and hold
harmless Lilly, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “Lilly Indemnitees”), against any
liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of
litigation) incurred by or imposed upon the Lilly Indemnitees, or any one of them, as a direct
result of claims, suits, actions or demands by Third Parties (collectively, the “Lilly
Claims”) arising out of (a) Archemix’s performance of SELEX Processes under this Agreement but
excluding Lilly Claims arising out of the alleged infringement of the Patent Rights of a Third
Party as a result of Archemix’s use of Feasibility Study Targets pursuant to this Agreement or (b)
the gross negligence or willful misconduct of Archemix or any of its Affiliates.

     6.3 Conditions to Indemnification. An Archemix Indemnitee or Lilly Indemnitee seeking
recovery under this Article 6 (the “Indemnified Party”) in respect of a Claim shall give
prompt notice of such Claim to the indemnifying party (the “Indemnifying Party”) and
provided that the Indemnifying Party is not contesting its obligation under this Article 6, shall
permit the Indemnifying Party to control any litigation relating to such Claim and the disposition
of such Claim (including without limitation any settlement thereof); provided, that, the
Indemnifying Party shall not settle or otherwise resolve such Claim without the prior written
consent of such Indemnified Party, which consent shall not be unreasonably withheld, conditioned or
delayed, unless such settlement includes a full release of the Indemnified Party, in which case the
indemnifying Party may settle or otherwise resolve such Claim without the prior written consent of
such Indemnified Party. Each Indemnified Party shall cooperate with the Indemnifying Party in its
defense of any such Claim in all reasonable respects and shall have the right to be present in
person or through counsel at all legal proceedings with respect to such Claim.

     6.4 Indemnification of Gilead and UTC by Lilly. If and solely to the extent, legally
required by the Archemix-Gilead Collaboration Agreement, Lilly shall indemnify, defend and hold
harmless Gilead, its Affiliates and UTC and any of their respective directors, officers, employees
and agents (each, a “Gilead Indemnitee”), from and against any losses that are incurred by
a Gilead Indemnitee as a result of any Claims, to the extent such Claims arise out of the
possession, research, development, storage or transport, by Lilly or its Affiliates of (a) any
Active Aptamers, or (b) any other products, services or activities developed by Lilly relating to
the Archemix Patent Rights, including any Active Aptamers.

     6.5 Warranty Disclaimer. NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY
TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. NEITHER PARTY MAKES ANY
WARRANTIES AS TO THE VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS LICENSED BY SUCH PARTY TO THE
OTHER PARTY.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

20

 

     6.6 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT,
EXCEPT WITH RESPECT TO THE PARTYS’ INDEMNIFICATION OBLIGATIONS UNDER SECTION 6.1, 6.2 AND/OR 6.4,
NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL,
PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST
PROFITS OR LOST REVENUES, OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES,
WHETHER UNDER ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE
THEORY.

7. TERM AND TERMINATION

     7.1 Term; Expiration. The term of this Agreement (the “Term”) shall commence
on the Effective Date and continue, unless earlier terminated as provided herein, until the latest
of (a) to the extent that the Feasibility Study Option is not exercised under this Agreement, the
expiration of the Feasibility Study Option Period; and (b) to the extent the Feasibility Study
Option is exercised under this Agreement until the expiration of the Feasibility Study Term.

     7.2 Termination.

          7.2.1 Unilateral Right to Terminate. Lilly shall have the right to terminate this
Agreement, for any reason, effective immediately upon written notice to Archemix.

          7.2.2 Termination for Challenge. In the event Lilly, its Affiliates and/or
Sublicensees initiates a Challenge or assists a Third Party in initiating a Challenge, Archemix
shall have the right to terminate this Agreement, effective immediately upon written notice to
Lilly.

          7.2.3 Termination for Breach. Except as set forth herein, either Party may terminate
this Agreement, effective immediately upon written notice to the other Party, for a material breach
by the other Party of this Agreement that, if curable, remains uncured for [***] days after the
non-breaching Party first gives written notice to the other Party of such breach and its intent to
terminate this Agreement if such breach is not cured.

          7.2.4 Termination for Insolvency. Each Party shall give the other Party reasonable
prior notice of the filing with respect to itself of any voluntary petition, and prompt notice of
the filing with respect to itself of any involuntary petition, under any bankruptcy laws. In the
event that either Party: (a) files for protection under bankruptcy laws; (b) makes an assignment of
all or substantially all of its assets for the benefit of creditors; (c) appoints or suffers
appointment of a receiver or trustee over all or substantially all of its assets; and (d) files a
petition under any bankruptcy or insolvency act or has any such petition filed against it which is
not discharged within [***] days of the filing thereof (each of (a)-(d), a “Bankruptcy
Action”), then the other Party may terminate this Agreement effective immediately upon written
notice to such Party. All rights and licenses granted under or pursuant to this Agreement are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
Code.

     7.3 Consequences of Termination of Agreement. In the event of the termination of

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

21

 

this Agreement pursuant to this Article 7, the following provisions shall apply:

               (a) all rights granted by Archemix to Lilly under this Agreement (including under the
Feasibility Study Option and the Collaboration/License Option) shall immediately terminate and
Archemix shall have no further obligations under Sections 2.2, 2.4 or 2.5;

               (b) the license granted by Lilly to Archemix pursuant to Section 2.1.1(b) hereunder shall
continue and survive in full force and effect (except in the event of termination by Lilly under
Section 7.2.3 during the Feasibility Study Term or the Collaboration/Negotiation License Period
when such license shall be revocable by Lilly);

               (c) Lilly shall promptly return all Confidential Information of Archemix; provided, that,
Lilly may retain one (1) copy of Confidential Information of Archemix in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder; and

               (d) Archemix shall promptly return all Confidential Information of Lilly; provided, that,
Archemix may retain one (1) copy of Confidential Information of Lilly in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.

     7.4 Remedies. Except as otherwise expressly set forth in this Agreement, the
termination provisions of this Article 7 are in addition to any other relief and remedies available
to either Party at law.

     7.5 Surviving Provisions. Notwithstanding any provision herein to the contrary, the
rights and obligations of the Parties set forth in Articles 3, 4 and 6 and Sections 2.1.1(b), 7.3,
7.4, 7.5, 9.1 and 9.2, as well as any rights or obligations otherwise accrued hereunder (including
any accrued payment obligations), shall survive the expiration or termination of the Term.

8. DISPUTES

     8.1 Negotiation. The Parties recognize that a bona fide dispute as to certain matters
may from time to time arise during the Term that relates to either Party’s rights and/or
obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by
written notice to the other Party, have such dispute referred to their respective senior officials
designated below or their successors or designees, for attempted resolution by good faith
negotiations within [***] days after such notice is received. Said designated senior officials are
as follows:

     For Lilly:           [***]

     For Archemix:      [***]

     8.2  Arbitration; Negotiation Disputes.

          8.2.1 Arbitration. Subject to Section 8.2.2 below, any dispute, controversy or claim
initiated by either Party arising out of, resulting from or relating to this Agreement or the
performance by either Party of its obligations under this Agreement (excluding Negotiation

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

22

 

Disputes), whether before or after termination of this Agreement, shall be finally resolved by
binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall
give written notice to that effect to the other Party. Any such arbitration shall be conducted
under the Commercial Arbitration Rules of the American Arbitration Association (the “AAA”)
by a panel of three arbitrators appointed in accordance with such rules. Any such arbitration
shall be held in Boston, Massachusetts if such arbitration is demanded by Lilly and in
Indianapolis, Indiana if such arbitration is demanded by Archemix. The method and manner of
discovery in any such arbitration proceeding shall be governed by the laws of the State of
Delaware. The arbitrator shall have the authority to grant injunctions and/or specific performance
and to allocate between the Parties the costs of arbitration in such equitable manner as they
determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or
application may be made to such court for judicial acceptance of any award and an order of
enforcement, as the case may be. In no event shall a demand for arbitration be made after the date
when institution of a legal or equitable proceeding based upon such claim, dispute or other matter
in question would be barred by the applicable statute of limitations. Notwithstanding the
foregoing, either Party shall have the right, without waiving any right or remedy available to such
Party under this Agreement or otherwise, to seek and obtain from any court of competent
jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights
or property of such Party, pending the selection of the arbitrators hereunder or pending the
arbitrators’ determination of any dispute, controversy or claim hereunder.

          8.2.2 Negotiation Disputes. To the extent a Negotiation Dispute arises pursuant to
Section 2.5.2, the following procedures shall apply:

               (a) The Parties shall mutually select a single independent, conflict-free arbitrator (the
“Third Party Expert”), who shall have sufficient background and experience in
pharmaceutical product research and collaboration agreements and who (and whose firm) is not at the
time of the Negotiation Dispute and did not at any time during the [***] years prior to the
Negotiation Dispute perform services for either Party, to resolve the Negotiation Dispute. If the
Parties are unable to reach agreement on the selection of a Third Party Expert within [***]
business days after submission to arbitration, then either or both Parties shall immediately
request that the AAA select an arbitrator with the requisite background and experience. The place
of arbitration shall be New York, New York.

               (b) Each Party shall prepare and submit a written summary of such Party’s position and any
relevant evidence in support thereof to the Third Party Expert within [***] days of the selection
of the Third Party Expert. Upon receipt of such summaries from each Party, the Third Party Expert
shall provide copies of the same to the other Party. Within [***] days of the delivery of such
summaries by the Third Party Expert, each Party shall submit a written rebuttal of the other
Party’s summary and may also amend and re-submit its original summary. Oral presentations shall
not be permitted unless otherwise requested by the Third Party Expert. The Third Party Expert
shall make a final decision with respect to the Negotiation Dispute within [***] days following
receipt of the last of such rebuttal statements submitted by the Parties. [***] shall bear [***]
percent ([***]%) of the costs and expenses and attorneys’ fees incurred in connection with the
Negotiation Dispute.

9. MISCELLANEOUS

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

23

 

     9.1 Notification. All notices, requests and other communications hereunder shall be
in writing, shall be addressed to the receiving Party’s address set forth below or to such other
address as a Party may designate by notice hereunder, and shall be either (a) delivered by hand,
(b) made by facsimile transmission, (c) sent by private courier service providing evidence of
receipt or (d) sent by registered or certified mail, return receipt requested, postage prepaid.
The addresses and other contact information for the parties are as follows:

	 	 	 	 	 
	 

	 	If to Lilly:
	 	If to Archemix:
	 
	 

	 	Eli Lilly and Company
	 	Archemix Corp.
	 

	 	Lilly Corporate Center
	 	300 Third Street
	 

	 	Indianapolis, Indiana 46285
	 	Cambridge, MA 02142
	 

	 	 	 	Tel: (617) 621-7700
	 

	 	Fax: 317-433-3000
	 	Fax: (617) 621-9300
	 

	 	Attention: General Counsel
	 	Attention: Chief Executive Officer
	 

	 	 	 	Attention: Legal Department
	 
	 	 	 	 
	 

	 	 	 	With a copy to:
	 
	 	 	 	 
	 

	 	 	 	Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
	 

	 	 	 	One Financial Center
	 

	 	 	 	Boston, MA 02110
	 

	 	 	 	Tel: (617) 542-6000
	 

	 	 	 	Fax: (617) 542-2241
	 

	 	 	 	Attn: John J. Cheney, Esq.

     All notices, requests and other communications hereunder shall be deemed to have been given
either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of
such Party set forth above, (ii) if made by facsimile transmission, at the time that confirmation
of receipt thereof has been received by the Party delivering such notice, (iii) if sent by private
courier, on the day such notice is delivered to the recipient or (iv) if sent by registered or
certified mail, on the fifth (5th) business day following the day such mailing is made.

     9.2 Governing Law. This Agreement will be construed, interpreted and applied in
accordance with the laws of the State of Delaware (excluding its body of law controlling conflicts
of law).

     9.3 Limitations. Except as expressly set forth in this Agreement, neither Party
grants to the other Party any right or license to any of its intellectual property.

     9.4 Entire Agreement. This Agreement is the entire agreement between the Parties with
respect to the subject matter hereof and supersedes all prior representations, understandings and
agreements between the Parties with respect to the subject matter hereof. No modification or
amendment shall be effective unless in writing with specific reference to this Agreement and signed
by the Parties.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

24

 

     9.5 Waiver. The terms or conditions of this Agreement may be waived only by a written
instrument executed by the Party waiving compliance. The failure of either Party at any time or
times to require performance of any provision hereof shall in no manner affect its rights at a
later time to enforce the same. No waiver by either Party of any condition or term shall be deemed
as a continuing waiver of such condition or term or of another condition or term.

     9.6 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form part of this Agreement.

     9.7 Assignment. Neither this Agreement nor any right or obligation hereunder may be
assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior
express written consent of the other not to be unreasonably withheld, conditioned or delayed;
provided, that, either Party may, without the written consent of the other, assign this Agreement
and its rights and delegate its obligations hereunder to its Affiliates or in connection with the
transfer or sale of all or substantially all of such Party’s assets or business to which this
Agreement relates or in the event of its merger, consolidation, change in control or similar
transaction. Any permitted assignee shall assume all obligations of its assignor under this
Agreement. Any purported assignment in violation of this Section 9.7 shall be void. The terms and
conditions of this Agreement shall be binding upon and inure to the benefit of the permitted
successors and assigns of the parties.

     9.8 Force Majeure. Neither Party shall be liable for failure of or delay in
performing obligations set forth in this Agreement, and neither shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes beyond the
reasonable control of such Party. In event of such force majeure, the Party affected thereby shall
use reasonable efforts to cure or overcome the same and resume performance of its obligations
hereunder.

     9.9 Construction. The Parties hereto acknowledge and agree that: (a) each Party and
its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed
to its revision; (b) the rule of construction to the effect that any ambiguities are resolved
against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)
the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and
not in favor of or against any Party, regardless of which Party was generally responsible for the
preparation of this Agreement.

     9.10 Severability. If any provision(s) of this Agreement are or become invalid, are
ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current
applicable law from time to time in effect during the Term hereof, it is the intention of the
Parties that the remainder of this Agreement shall not be affected thereby; provided, that, a
Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and
agree to renegotiate any such term, covenant or application thereof in good faith in order to
provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or
the application thereof that is invalid, illegal or unenforceable, it being the intent of the
Parties that the basic purposes of this Agreement are to be effectuated.

     9.11 Status. Nothing in this Agreement is intended or shall be deemed to constitute a
partner, agency, employer-employee or joint venture relationship between the Parties.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

25

 

     9.12 Further Assurances. Each Party agrees to execute, acknowledge and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

     9.13 Counterparts. This Agreement may be executed simultaneously in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective
duly authorized representative in 

two (2) originals.

	 	 	 	 	 	 	 	 	 	 	 
	ELI LILLY AND COMPANY	 	 	 	ARCHEMIX CORP.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Steven M. Paul, M.D.	 	 	 	By:	 	/s/ John A. Harre	 	 
	Name:

	 	Steven M. Paul

	 	 	 	Name:
	 	John
A. Harre

	 	 
	Title:

	 	Executive
VP Science & Technology

	 	 	 	Title:
	 	VP,
Legal Affairs

	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

26

 

Exhibit A

Feasibility Study Plan

Archemix-Lilly Feasibility Study

Objective: Demonstrate the [***].

Target choice: In evaluating potential targets for the feasibility study, it is worth considering
(1) the [***], and (2) [***].

Potential competitive considerations. The [***] and [***] make the following [***] for an
[***].

	 	•	 	[***]
	 
	 	•	 	[***]
	 
	 	•	 	[***]
	 
	 	•	 	[***]
	 
	 	•	 	[***]

Technical feasibility. Overall, there [***] to be [***] or [***] have been [***], and others.
Some [***] that [***] include the following:

	 	•	 	[***]
	 
	 	•	 	[***]
	 
	 	•	 	[***]
	 
	 	•	 	[***]

While [***] have been [***] and [***] in [***] remains [***] and, as such, [***] are [***] where
[***]. Given all of the above [***].

Proposed research outline: The following table summarizes the key steps in the feasibility study,
including responsibilities and the projected timeline.

	 	 	 	 	 	 	 
	Activity	 	Responsibility	 	Timing	 	Description
	[***]
	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

Exhibit A-1

 

 

Schedule 1

AME Patent Rights

	 	 	 	 	 	 	 	 	 
	United States Patent Nos.
	 	 	[***];	 	 	 	 	 
	 
	 	 	[***];	 	 	 	 	 
	 
	 	 	[***];	 	 	 	 	 
	 
	 	 	[***];	 	 	 	 	 
	 
	 	 	[***];	 	 	 	 	 
	 
	 	 	[***];	 	 	 	 	 
	 
	 	 	[***]	 	and
	 
	 
	 	 	[***]	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

Schedule 1-1

 

 

Schedule 2

Terms to be Included in Collaboration Agreement

Any Collaboration Agreement negotiated under the Collaboration/License Option will include the
following pre-defined terms:

1. Initial Fee – Lilly will pay Archemix a non-refundable payment of [***] dollars $[***]
for [***] within [***] days of the effective date of the Collaboration Agreement. [***].

2. Research Collaboration – Archemix will have the [***] for [***]. Lilly will [***]. The
number of [***], but in any event shall be [***] shall be determined by [***].

3. Governance – A [***]. Activities will be conducted [***]. All technical/scientific
decisions of the [***]; provided, however, that [***].

4. Diligence – Lilly and Archemix shall [***]. Lilly shall [***].

5. Milestones – Within [***] of a Product successfully completing each of the following
events or stages, Lilly will pay Archemix the following non-refundable milestone payments.
Milestones will be payable [***]. [***].

	 	 	 	 	 
	Milestones	 	Amount ($M)
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	 
	[***]
	 	 	[***]	*
	[***]
	 	 	[***]	*
	 
	 	 	 	 
	 
	 	 	[***]	 

 

			
	*	 	[***]
	 
	 	 	[***].

If payment is made [***].

6. Royalties – For each Licensed Product, Lilly will pay Archemix [***] the following
royalties on net sales of Licensed Products during the applicable Royalty Term.

	 	 	 	 	 
	Annual Tiered Net Sales	 	Royalties on Sales Increments
	$[***]
	 	 	[***]	%
	$[***]
	 	 	[***]	%
	$[***]
	 	 	[***]	%

The annual sales increments will be [***].

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

Schedule 2-1

 

 

7. Royalty Term – The royalty bearing period for each Licensed Product will [***] or [***],
whichever is longer. [***].

8. Termination – Lilly will have the right to [***]. Upon termination of the agreement,
the [***]. For clarity, the [***].

9. Other Targets – [***], Lilly and Archemix may include [***].

10. Confidential Information, IP Ownership – During the term of the Collaboration Agreement
and for a period of [***] after the end of the term, either party receiving confidential
information from the other party will (a) maintain in confidence such confidential information to
the same extent that the receiving party maintains its own proprietary information of similar kind
and value [***], (b) use such confidential information only for purposes of the agreement, and (c)
not to disclose such confidential information to any third party without prior written consent of
the other party.

     All Archemix confidential information, Archemix technology, and improvements to the SELEX
technology (including without limitation the SELEX process), aptamer generic technology and
aptamers developed in the course of performing the research and development program, [***]. All
Lilly confidential information and Lilly technology [***].

     For clarity, Archemix shall [***] (i) [***] and (ii) [***].

11. Change in Control – The agreement will contain change of control provisions [***].

12. Press Release – If warranted, Archemix and Lilly will [***].

13. Additional Terms – The Agreement would also include [***]. The Collaboration Agreement
will be governed by and construed in accordance with the laws of the State of Delaware.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 2-2

 

 

Schedule 3

Archemix SELEX Portfolio

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

Schedule 3-1

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-2

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-3

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-4

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-5

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-6

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-7

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-8

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-9

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-10

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-11

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Archemix	 	 	 	 	 	 	 	 	 	Title/Subject
	Mintz Ref. No.	 	Ref. No.	 	Status	 	Appl. Number	 	Filing Date	 	Country	 	Matter
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 
	 	 	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-12

 

Schedule 4

Gilead SELEX Portfolio

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under
Rule 406 of the Securities Act.

Schedule 4-1

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-2

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	 	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-3

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-4

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-5

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-6

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-7

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-8

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	 	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-9

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-10

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-11

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS	 	FILE	 	ISSUE
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 4-12exv10w48

Exhibit 10.48

Execution Copy

EXCLUSIVE LICENSE AGREEMENT

     This Exclusive License Agreement (this “Agreement”) is made effective as of December
10, 2007 (the “Effective Date”), by and between Archemix Corp, a Delaware corporation with
offices at 300 Third Street, Cambridge, MA 02142 (“Archemix”), and Ribomic, Inc., a
corporation organized under the laws of Japan with offices at 3-15-5-601 Shirokanedai, Minato-Ku,
Tokyo 108-007 Japan (“Ribomic”). Archemix and Ribomic are each sometimes hereinafter
referred to individually as a “Party” and collectively as the “Parties.”

     WHEREAS, Archemix is the owner of or otherwise controls, certain patents and proprietary
technology;

     WHEREAS, Ribomic desires to obtain an exclusive license from Archemix under such patents and
technology to develop and commercialize certain products; and

     WHEREAS, Archemix desires to grant such license to Ribomic on the terms and subject to the
conditions of this Agreement.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties
hereby agree as follows:

1. DEFINITIONS

     Whenever used in the Agreement with an initial capital letter, the terms defined in this
Article 1 shall have the meanings specified.

     1.1 “Acceptance”means (a) with respect to the United States, [***] days from the date
an NDA is received by the FDA if no refuse-to-file order is issued by the FDA or, to the extent
issued, such later date on which the deficiencies referred in such refuse-to-file notice are
corrected or the NDA is otherwise deemed “filed” by the FDA; and (b) with respect to an E5 Country
or Japan, the equivalent of the above or any other action or non-action that allows a party to
proceed with a product launch.

     1.2 “Adverse Event” means any untoward, undesired or unplanned medical occurrence in a
human clinical trial subject or patient, which occurrence has a temporal relationship to
administration of a Licensed Product, whether or not considered related to the Licensed Product,
including, without limitation, any undesirable sign (including abnormal laboratory findings of
clinical concern), symptom or disease that may be associated with the use of such Licensed Product.

     1.3 “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly, controls or is controlled by or is under common control with, such Person. For
purposes of this definition, “control” means (a) ownership of fifty percent (50%) or more of the
shares of stock entitled to vote for the election of directors in the case of a corporation or
fifty percent (50%) or more of the equity interests in the case of any other type of legal entity,
(b) status as a general partner in any partnership, or (c) any other arrangement whereby a Person
controls or has the right to control the board of directors of a corporation or equivalent
governing body of an entity other than a corporation.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

     1.4 “Annual Net Sales” means, with respect to any Calendar Year, the aggregate amount
of the Net Sales for such Calendar Year.

     1.5 “Applicable Laws” means federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, guidance, guidelines or
requirements of regulatory authorities, national securities exchanges or securities listing
organizations, that may be in effect from time to time during the Term and are applicable to a
particular activity hereunder.

     1.6 “Applicable Sublicense Income Rate”means (a) with respect to any Early Stage
Sublicense Agreement, [***] percent ([***]%) and (b) with respect to any Late Stage Sublicense
Agreement, [***] percent ([***]%).

     1.7 “Aptamer” means (a) any naturally or non-naturally occurring oligonucleotide
identified through the SELEX Process that binds with high specificity and affinity to a Target, and
(b) any oligonucleotide Derived from an oligonucleotide of clause (a) that has such high
specificity and affinity to a Target.

     1.8 “Archemix-Gilead License Agreement” means the License Agreement between Gilead
Sciences, Inc. and Archemix dated October 21, 2001, as amended.

     1.9 “Calendar Quarter” means the period beginning on the Effective Date and ending on
the last day of the calendar quarter in which the Effective Date falls, and thereafter each
successive period of three (3) consecutive calendar months ending on March 31, June 30, September
30 or December 31.

     1.10 “Calendar Year” means the period beginning on the Effective Date and ending on
December 31 of the year in which the Effective Date falls and thereafter each successive period of
twelve (12) months commencing on January 1 and ending on December 31.

     1.11 “Challenge” means any challenge to the validity or enforceability of any Licensed
Patent Right in the absence of a breach of this Agreement including, without limitation, by (a)
filing a declaratory judgment action in which any Licensed Patent Right is alleged to be invalid or
unenforceable; (b) citing prior art pursuant to [***], filing a request for re-examination of any
Licensed Patent Right pursuant to [***] and/or [***] or provoking or becoming party to an
interference with an application for any Licensed Patent Right pursuant to [***]; or (c) filing or
commencing any reexamination, opposition, cancellation, nullity or similar proceedings against any
Licensed Patent Right in any country.

     1.12 “Commercially Reasonable Efforts” means, with respect to activities of Ribomic
under this Agreement, the efforts and resources customarily used by similarly sized biotechnology
companies in the performance of such activities for other products owned by such companies which
are of similar market potential and at a similar stage of development, taking into account the
competitiveness of the market place, the regulatory structure involved and other relevant and
material factors.

     1.13 “Commercialization Regulatory Approval” means, with respect to any Product, the
Regulatory Approval required by Applicable Laws to sell such Licensed Product for use in the Field
in a country or region in the Territory. “Commercialization Regulatory Approval” shall include,
without limitation, the approval of any Drug Approval Application. For purposes of clarity,
“Commercialization Regulatory Approval” in the United States shall mean final approval

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

2

 

of an NDA for the first Indication in the United States, “Commercialization Regulatory
Approval” in the European Union shall mean marketing authorization for the applicable Product
pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended
and “Commercialization Regulatory Approval” in Japan shall mean final approval of an application
submitted to the Ministry of Health, Labor and Welfare and the publication of a New Drug Approval
Information Package permitting marketing of the applicable Product in Japan, as any of the
foregoing may be amended from time to time.

     1.14
“Commercialization Regulatory Filing”means, with respect to any Licensed
Product, the filing required to obtain Commercialization Regulatory Approval for use in the Field
in a country or region in the Territory.

     1.15 “Completion” means, with respect to a clinical trial, the closing of the database
with respect to the applicable clinical trial.

     1.16 “Confidential Information” means all information and Technology disclosed or
provided by, or on behalf of a Party (the “Disclosing Party”) to the other Party (the
“Receiving Party”) or to any of the Receiving Party’s employees, consultants, Affiliates or
sublicensees pursuant to or in connection with this Agreement; provided, that, none of the
foregoing shall be Confidential Information if: (a) as of the date of disclosure, it is known to
the Receiving Party or its Affiliates, as demonstrated by credible written documentation, other
than by virtue of a prior confidential disclosure to such Receiving Party; (b) as of the date of
disclosure it is in the public domain or it subsequently enters the public domain other than
through a breach by the Receiving Party or its Affiliates of a contractual obligation; (c) it is
obtained by the Receiving Party from a Third Party having a lawful right to make such disclosure
free from any obligation of confidentiality to the Disclosing Party or its Affiliates; or (d) it is
independently developed by or for the Receiving Party or its Affiliates without reference to or use
of any Confidential Information of the Disclosing Party or its Affiliates as demonstrated by
credible written documentation. For purposes of clarity, unless excluded from Confidential
Information pursuant to the provisos of the preceding sentence, any scientific, technical or
financial information Controlled by a Disclosing Party and disclosed at any meeting of the Parties
or disclosed through an audit report shall constitute Confidential Information of the Disclosing
Party.

     1.17 “Control” or “Controlled” means with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without the payment of additional consideration to, and without
violating the terms of any agreement or arrangement with, any Third Party and without violating any
Applicable Laws.

     1.18 “Defined Territory” means, collectively, the United States, any E5 Country and
Japan.

     1.19 “Derived” means identified, developed, created, synthesized, designed, resulting
or generated from, conjugated to, or complexed with (whether directly or indirectly or in whole or
in part).

     1.20 “Development” and “Develop” means, with respect to any Licensed Product,
all activities with respect to such Licensed Product relating to the development in connection with

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

3

 

seeking, obtaining and/or maintaining Commercialization Regulatory Approval for such Licensed
Product in the Field in the Territory, including, without limitation, all pre-clinical research and
development activities, all human clinical studies, all activities relating to developing the
ability to manufacture any Licensed Product or any component thereof (including, without
limitation, process development work), and all other activities relating to seeking, obtaining
and/or maintaining any Regulatory Approvals from the FDA and/or any Foreign Regulatory Authority.

     1.21 “Diagnosis” means (a) the determination or monitoring of (i) the presence or
absence of a disease, (ii) the stage, progression or severity of a disease or (iii) the effect on a
disease of a particular treatment; and/or (b) the selection of patients for a particular treatment
with respect to a disease.

     1.22 “Diagnostics” means In Vitro Diagnostics, In Vivo Diagnostic Agents and any
product used for Diagnosis.

     1.23 “Early Stage Sublicense Agreement”means any Sublicense Agreement that is not a
Late Stage Sublicense Agreement.

     1.24 “E5 Country” means each of the United Kingdom, Germany, France, Italy and Spain.

     1.25 “Existing License Agreement”means the Non-Exclusive IgG Antibody Purification
License Agreement dated as of October 31, 2006, by and between Ribomic and Archemix.

     1.26 “Field” means the prevention, treatment or cure of any Indication in animals and
humans, but excluding, without limitation, Diagnostic Products, In Vivo Imaging Applications and
all non-therapeutic uses.

     1.27 “First Commercial Sale” means, on a country-by-country basis, the date of the
first arm’s length transaction, transfer or disposition for value to a Third Party of a Licensed
Product by or on behalf of, Ribomic, its Affiliate(s) or Sublicensee(s) in such country after
obtaining the Commercialization Regulatory Approval for the Licensed Product. For purposes of
clarity, the use of any Licensed Product in clinical trials, pre-clinical studies or other research
or development activities or the disposal or transfer of a Licensed Product for a bona fide
charitable purpose or for purposes of a commercially reasonable sampling program shall not be
deemed to be an arm’s length transaction, transfer or disposition for value for purposes of this
definition.

     1.28 “FDA” means the United States Food and Drug Administration and any successor
agency or authority thereto.

     1.29 “Full Royalty Net Sales”means Net Sales in any country in which the Full Royalty
Term has not expired.

     1.30 “Full Royalty Term”means, with respect to each Licensed Product in each country
in the Territory, the period beginning on the date of First Commercial Sale of such Licensed
Product in such country and ending on the expiration of the last to expire Valid Claim

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

4

 

of the Licensed Patent Rights in such country.

     1.31 “IND” means an investigational new drug application (as defined in Title 21 of
the United States Code of Federal Regulations, as amended from time to time) filed or to be filed
with the FDA with regard to any Licensed Product and any counterpart of an investigational new drug
application that is required in any other country or region in the Territory before beginning
clinical testing of a Licensed Product in humans in such country or region.

     1.32 “Indication” means any indication, disease, disorder or condition in the Field,
which can be treated, controlled, prevented, cured or the progression of which can be delayed.

     1.33 “Initiation” means, with respect to a human clinical trial, the first date that a
subject or patient is dosed in such clinical trial.

     1.34 “In Vitro Diagnostics” means the use of the SELEX Process or Aptamers in the
assay, testing or determination, outside of a living organism, of a substance in a test material.
In Vitro Diagnostics shall include, among other things, the use of the SELEX Process or Aptamers in
the assay, testing or determination: (a) outside of a living organism, (i) of a human substance in
a test material, often to identify or follow the progression of a disease or disorder or to select
a patient for treatment; (ii) of a plant substance, animal substance or other substance in a test
material, often to identify or follow the progression of a disease, process or disorder in a human
or non-human organism; and (iii) of environmental substances (as in water quality testing); (b) of
a substance on a test material such as cells (as in FACS analysis or other measurements of
pathogens within biological samples); and (c) any other in vitro diagnostic use of the SELEX
Process or Aptamers in drug development processes, including target identification, pre-clinical
and clinical testing, and the following more specific examples of uses of Aptamer technology: (i)
to observe, through protein profiling, protein levels moving up or down in diseases or models of
diseases, and to evaluate whether such proteins are sensible targets for the development of
therapeutic agents; (ii) to observe coordinated expression of protein pathways in a variety of
biological states in various systems; (iii) to study protein or metabolite levels during
pre-clinical drug candidate evaluation in response to putative therapeutic agents during clinical
trials (e.g., as markers of efficacy or response); and (iv) to study human protein or metabolite
levels in response to putative therapeutic agents during clinical trials (e.g., as markers of
efficacy or response). Notwithstanding the above, In Vitro Diagnostics shall exclude any of the
above-described uses in this Section 1.34(c) conducted in the Development of Program Aptamers under
this Agreement.

     1.35 “In Vivo Diagnostics” means the use of any product containing one or more
Aptamers for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease state.

     1.36 “Joint Patent Rights” means Patent Rights that contain one or more claims that
cover Joint Technology.

     1.37 “Joint Technology” means any Technology (including, without limitation, any new
and useful process, method of manufacture or composition of matter) that is jointly conceived or
first reduced to practice (actively or constructively) by employees of or consultants

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

5

 

to Ribomic and employees of or consultants to Archemix at any meeting of the DC.

     1.38 “Knowledge” means, with respect to Archemix, the actual knowledge of the chief
executive officer, any vice president or the chief legal officer of Archemix.

     1.39 “Late Stage Sublicense Agreement”means any Sublicense Agreement involving a
Licensed Product that is executed on or after the Initiation of a Phase II Clinical Trial with
respect to such Licensed Product.

     1.40 “Licensed Patent Rights” means all Patent Rights Controlled by Archemix or any of
its Affiliates during the Term that cover or claim Licensed Products in the Field including,
without limitation, the Development, manufacture, use, offer for sale, sale or importation thereof.
For purposes of clarity, the Licensed Patent Rights, as of the Effective Date, include without
limitation the Patent Rights listed on Exhibit A attached hereto.

     1.41 “Licensed Product” means any pharmaceutical product containing, incorporating,
comprised of, identified through the material use of or Derived from, in whole or in part, any
Program Aptamer.

     1.42 “Licensed Technology” means any Technology Controlled by Archemix or any of its
Affiliates during the Term that is necessary or useful for the Development, manufacture, use, offer
for sale, sale or importation of Licensed Products in the Field.

     1.43 “Major Market Country”means each of the United States, the United Kingdom,
Germany, Spain, France, Italy, Canada and Japan.

     1.44 “Net Sales” means the gross amount billed or invoiced by Ribomic or any of its
Affiliates or Sublicensees to Third Parties throughout the Territory for sales or other
dispositions or transfers for value of Licensed Products less (i) allowances for normal and
customary trade, quantity and cash discounts actually allowed and taken, and inventory management
fees paid to wholesalers and distributors; (ii) transportation, insurance and postage charges, if
paid by Ribomic or any Affiliate or Sublicensee and included on any such Person’s bill or invoice
as a separate item; (iii) credits, chargebacks, retroactive price reductions, rebates and returns,
to the extent actually allowed; (iv) negotiated payments made to private sector and government
Third Party payors (e.g., PBMs, HMOs and PPOs) and purchasers/providers (e.g., staff model HMOs,
hospitals and clinics), regardless of the payment mechanism, including, without limitation,
off-invoice, rebate, chargeback and credit mechanisms, including, without limitation, with respect
to any Net Sales in Japan, any sales-based contribution for “Drug Induced Suffering” and any
sales-based contribution for “Contribution for Measure for Drug Safety,” in each case as required
by Applicable Laws or any regulatory authority, in the amount determined by and payable to the
Pharmaceuticals and Medical Devices Agency (so-called “KIKO”); (v) discounts paid under discount
prescription drug programs and reductions for coupon and voucher programs; and (vi) any tax,
tariff, customs duty, excise or other duty or other governmental charge (other than a tax on
income) levied on the sale, transportation or delivery of Licensed Product and actually paid by
Ribomic or any of its Affiliates or Sublicensees. In addition, Net Sales are subject to the
following:

          (a) If Ribomic or any of its Affiliates or Sublicensees effects a sale,

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

6

 

disposition or transfer of a Licensed Product to a customer in a particular country as part of
a package of Licensed Products and services (but not in a Combination Product), the Net Sales of
such Licensed Product to such customer shall be deemed to be “the fair market value” of such
Licensed Product less applicable discounts pursuant to this definition of Net Sales. For purposes
of this subsection (a), “fair market value” shall mean the fraction (A/A+B), where A equals the
value that would have been derived had such Licensed Product been sold as a separate Licensed
Product to another customer in the country concerned on customary commercial terms, during the
applicable Calendar Quarter in the country concerned, and B equals the aggregate value that would
have been derived had the other components of such package been sold as separate products to
another customer in the country concerned on customary commercial terms, during the applicable
Calendar Quarter in the country concerned.

          (b) In the case of pharmacy incentive programs, hospital performance incentive program
chargebacks, disease management programs, similar programs or discounts on “bundles” of Licensed
Products, all discounts and the like shall be allocated among Licensed Products on the basis of
which such discounts and the like were actually granted or, if such basis cannot be determined, in
proportion to the respective list prices of such Licensed Products.

          (c) For clarity, use of any Licensed Product in clinical trials, pre-clinical studies or other
research or development activities or disposal or transfer of Licensed Products for a bona fide
charitable purpose or purposes of a commercially reasonable sampling program shall not give rise to
any Net Sales.

          (d) Sales or transfers of Licensed Product among Ribomic, its Affiliates and Sublicensees for
the purpose of subsequent resale to Third Parties shall not be included in Net Sales; with respect
to such sales or transfers, the gross amounts billed or invoiced in connection with the subsequent
resale to Third Parties will be included in the calculation of Net Sales.

     In the event that a Licensed Product under this Agreement is sold in combination
(“Combination Product”) with another ingredient or component having independent,
supplementary or enabling therapeutic effect (e.g., as a catalyst or adjuvant) or diagnostic
utility or that has independent function as a medical device or means of administration (a
“Supplemental Component”), then “Net Sales,” for purposes of determining royalty payments
on the Combination Product, shall be calculated using one of the following methods:

          (y) By multiplying the Net Sales of the Combination Product (calculated prior to the
application of this formula) by the fraction C/C+D, where C is the average gross selling price,
during the applicable Calendar Quarter in the country concerned, of the Licensed Product when sold
separately, and D is the average gross selling price, during the applicable Calendar Quarter in the
country concerned, of the Supplemental Component(s) when sold separately; or

          (z) In the event that no such separate sales are made of the Licensed Product or any of the
Supplemental Components in such Combination Product during the applicable Calendar Quarter in the
country concerned, Net Sales, for the purposes of determining royalty payments, shall be calculated
using the above formula where C is the reasonably estimated commercial value of the Licensed
Product sold separately, during the applicable Calendar Quarter in the country concerned, and D is
the reasonably estimated commercial value of the Supplemental Components sold separately, during
the applicable Calendar Quarter in the country

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

7

 

concerned,. Any such estimates shall be determined using criteria to be mutually agreed upon
by the Parties. Such estimates shall be reported to Archemix in the reports to be provided
pursuant to Section 4.5.1 hereof. If the Parties are unable to agree on the criteria for
determining such estimates, either Party may submit such dispute for resolution pursuant to the
provisions of Section 10.2.2.

     1.45 “Non-Royalty Term” means, with respect to each Licensed Product that has been
sublicensed under a Sublicense Agreement, the period commencing on the Effective Date and
continuing on a Licensed Product-by-Licensed Product and country-by-country basis until the date on
which no further payments of Sublicense Income are received by Ribomic.

     1.46 “Partial Royalty Net Sales”means Net Sales in any country in which the Full
Royalty Term has expired but the Partial Royalty Term has not expired.

     1.47 “Partial Royalty Term”means, with respect to each Licensed Product in each
country in the Territory, the period commencing on the day after the last day of the Full Royalty
Term for such Licensed Product in such country and expiring ten (10) years from the date of the
First Commercial Sale of such Licensed Product in such country.

     1.48 “Patent Rights” means all rights and interests in and to issued patents and
pending patent applications including, without limitation, non-provisional patent applications, and
all divisions, continuations and continuations-in-part thereof, patents issuing on any of the
foregoing, all reissues, reexaminations, renewals and extensions thereof, and supplementary
protection certificates therefor, as well as any certificates of invention or applications
therefor, and all foreign equivalents of any of the foregoing.

     1.49 “Permitted Archemix Activities”means (a) with respect to any Program Target, any
screening activities conducted by Archemix with respect to such Program Target for itself and/or
for any Third Party for the purpose of identifying aptamers that bind to a Target other than a
Program Target; and (b) any grant by Archemix to any Third Party of rights to discover, develop
and/or commercialize aptamers that bind to Targets (including Program Targets) outside of the
Field.

     1.50 “Permitted Ribomic Activities”means, on a country-by-country and Valid
Claim-by-Valid Claim basis, any activity conducted by Ribomic or any of its Affiliates or
Sublicensees (a) involving the discovery, research, development and commercialization of aptamers
in a country for use in the Field against any Target other than the Program Target at any time on
and after the expiration of the last to expire applicable Valid Claim of the Licensed Patent Rights
in such country or (b) pursuant to the terms of the Existing License Agreement, for so long as the
Existing License Agreement continues in full force and effect.

     1.51 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a
government.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

8

 

     1.52 “Phase I Clinical Trial” means a clinical trial conducted in healthy humans,
which clinical trial is designed to initially explore the safety, drug-drug interactions and/or
pharmacokinetics of an investigational drug given its intended use, and to support continued
testing of such drug in Phase II Clinical Trials.

     1.53 “Phase II Clinical Trial” means a clinical trial conducted in patients with a
particular disease or condition, which clinical trial is designed to establish the safety,
appropriate dosage and pharmacological activity of an investigational drug given its intended use,
and to initially explore its efficacy for such disease or condition.

     1.54 “Phase IIa Clinical Trial”means, as to a particular Licensed Product, the
portion of a Phase II Clinical Trial which contains a sufficient number of subjects to generate
sufficient data (if successful) to commence a Phase IIb or a Phase III Clinical Trial of
such Licensed Product or otherwise satisfies the proof of concept applicable to such Licensed
Product.

     1.55 “Phase IIb Clinical Trial”means, as to a particular Licensed Product, the
portion of a Phase II Clinical Trial which contains a sufficient number of subjects to generate
sufficient data (if successful) to commence a Phase III Clinical Trial of such Licensed Product or
act as a basis for obtaining Commercialization Regulatory Approval of such Licensed Product.

     1.56 “Phase III Clinical Trial” means a pivotal clinical trial conducted in patients
with a particular disease or condition, which clinical trial is designed to ascertain efficacy and
safety of an investigational drug for its intended use and to define warnings, precautions and
Adverse Events that are associated with the investigational drug in the dosage range intended to be
prescribed, with the purpose of preparing and submitting applications for Regulatory Approval or
label expansion to the FDA in the United States or pertinent Foreign Regulatory Authority in a
country outside the United States.

     1.57 “Program Aptamer” means any Aptamer that binds to a Program Target and any
Aptamer(s) Derived therefrom that binds to a Program Target.

     1.58
“Program Target” means the protein [***], as more fully described on
Schedule 1 attached hereto.

     1.59 “Radio Therapeutics” means any product for human therapeutic use that contains
one or more Aptamers that targets specifically any diseased tissue, cells or disease-specific
molecules or any tissue or cells which are affected by a disease or located in the close
neighborhood of a disease process and is linked to or incorporates (a) radionucleotides or (b) any
structure or elements which develop therapeutic effects similar to the effect of linking or
incorporating radionucleotides after submission of any kind of radiation.

     1.60 “Regulatory Approval” means any and all approvals (including pricing and
reimbursement approvals), product and establishment licenses, registrations or authorizations of
any kind of the FDA or any Foreign Regulatory Authority necessary for the development, pre-clinical
and/or human clinical testing, manufacture, quality testing, supply, use, storage, importation,
export, transport, marketing and sale of a Licensed Product (or any component

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

9

 

thereof) for use in the Field in any country or other jurisdiction in the Territory.

     1.61 Ribomic SELEX Patent Rights” means any Patent Rights that contain one or more
claims that cover Ribomic SELEX Technology. For purposes of clarity, the Ribomic SELEX Patent
Rights, as of the Effective Date, include without limitation the Patent Rights listed on
Exhibit B attached hereto.

     1.62 Ribomic SELEX Technology” means any Technology that is Controlled by Ribomic as
of the Effective Date or during the Term relating to or constituting aptamer compositions or that
is useful for the identification, generation, modification, optimization, stabilization or use of
aptamers.

     1.63 “ROFR Period”means the period commencing on the Effective Date and continuing
until the date of execution by Ribomic of a Sublicense Agreement involving any Licensed Product and
containing Minimum Acceptable Financial Terms.

     1.64 “Royalty Term”means, with respect to each Licensed Product in each country in
the Territory, the period beginning on the first day of the Full Royalty Term for such Licensed
Product in such country and ending on the last day of the Partial Royalty Term for such Licensed
Product in such country.

     1.65 “SELEX Portfolio” means those Patent Rights licensed by Gilead to Archemix
pursuant to the Archemix-Gilead License Agreement.

     1.66 “SELEX Process” means any process used for the identification or generation of a
nucleic acid that binds to a Target by means other than Watson-Crick base-pairing including,
without limitation, those that are covered by the claims in (a) the SELEX Portfolio, including,
without limitation, U.S. Patent Nos. [***] or [***], (b) any other Patent Rights Controlled by
Archemix or (c) any continuation, divisional, continuation-in-part, substitution, renewal, reissue,
re-examination or extension, or any foreign equivalent, of any of the foregoing Patent Rights.

     1.67 “SELEX Technology” means any process for modifying, optimizing and/or stabilizing
an Aptamer wherein such modification, optimization or stabilization includes, without limitation,
minimization, truncation, conjugation, pegylation, complexation, substitution, deletion and/or
incorporation of modified nucleotides.

     1.68 “Sublicense Agreement”means any agreement between Ribomic and a Sublicensee.

     1.69 “Sublicensee” means any Third Party to which Ribomic grants a sublicense of some
or all of the rights granted to Ribomic under this Agreement.

     1.70 “Sublicense Income”means [***] consideration and payments (including all upfront
payments, milestone payments, and license or maintenance payments) received by Ribomic from any
Sublicensees excluding (a) payments [***] a Sublicensee which are required to be used to [***] or
[***] to be [***] by such Party [***] to a [***] for [***] which has been agreed to with the
Sublicensee to the extent that the [***] for such [***] do not [***] the then [***] thereof, (b)
payments made in consideration of the [***] of Ribomic to the extent that the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

10

 

[***] for [***] does not [***] the then [***] thereof and (c) [***] on [***] by such
Sublicensee made to Ribomic pursuant to the terms of the applicable sublicense agreement.
Notwithstanding the foregoing, if a Sublicensee [***] of Ribomic and the [***] of [***] of [***] or
if [***] to [***] and [***] the [***] of such [***] (such [***] being referred to as the [***]),
then such [***] shall be [***] as [***]. For purposes of Section 1.70(b), the “Fair Market Value”
of Ribomic’s shares on the date of sale shall be determined as follows: (i) if such shares are
publicly traded on a recognized securities exchange or over the counter market, the fair market
value of such shares shall be the closing price of such shares reported on the applicable date of
sale; (ii) if such shares are not publicly traded on a recognized securities exchange or over the
counter market, the Fair Market Value shall be the price per share of such shares paid on the date
of sale or within three (3) months prior to the date of sale by a third party having no interest in
Ribomic other than as a result of having purchased such shares; and (iii) if neither (i) or (ii)
are applicable, the Fair Market Value shall be the price per share that a willing buyer would pay
to a willing seller in an arm’s length transaction. If the Parties are unable to agree on Fair
Market Value under clause (iii), the matter will be resolved in accordance with Section 10.2.2.
For purposes of Section 1.70(a), the term “Fair Market Value” with respect to research and
development funding shall mean the reasonable value of the applicable research and development
activities based on full-time equivalent or other cost-accounting methodologies that are consistent
with the approved budget and then-applicable current industry practices.

     1.71 “Target” means a protein, cytokine, enzyme, receptor, transducer, transcription
factor, antigen or any other non-nucleic acid molecule.

     1.72 “Technology” means, collectively, inventions, discoveries, improvements, trade
secrets and proprietary methods, whether or not patentable, including, without limitation: (a)
methods of production or use of, and structural and functional information pertaining to, chemical
compounds and (b) compositions of matter, data, formulations, processes, techniques, know-how and
results (including any negative results).

     1.73 “Territory” means all countries and jurisdictions of the world.

     1.74 “Third Party” means any person or entity other than Ribomic, Archemix and their
respective Affiliates.

     1.75 “ULEHI” means University License Equity Holdings, Inc., formerly known as UTC.

     1.76 “URC License Agreement” means the Restated Assignment and License Agreement,
dated July 17, 1991, by and between University Research Corporation and Gilead Sciences, Inc. as
successor in interest to NeXstar Pharmaceuticals, Inc.

     1.77 “UTC” means University Technology Corporation, the successor to the University
Research Corporation.

     1.78 “Valid Claim” means any claim of a pending patent application or an issued,
unexpired patent covered under the Licensed Patent Rights which, but for the license granted by
Archemix hereunder, would be infringed by the discovery, research, manufacture, use, delivery,

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

11

 

import, offer for sale or sale of a Licensed Product or any component thereof, to the extent
that such application or patent (a) has not been finally cancelled, withdrawn, abandoned or
rejected by any administrative agency or other body of competent jurisdiction, (b) has not been
permanently revoked, held invalid or declared unpatentable or unenforceable in a decision of a
court or other body of competent jurisdiction that is unappealable or unappealed within the time
allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, or (d)
is not lost through an interference proceeding.

     Additional Definitions. In addition, each of the following definitions shall have the
respective meanings set forth in the section of this Agreement indicated below:

	 	 	 
	Definition	 	Section
	AAA
	 	10.2.1
	Agreement
	 	Recitals
	Archemix
	 	Recitals
	Archemix License
	 	2.1.2(a)
	Archemix Indemnitees
	 	8.1
	Bankruptcy Action
	 	9.2.4
	Claims
	 	8.1
	Covered License Product
	 	4.2.2
	DC (Diligence Committee)
	 	3.4
	Development Plan
	 	3.2
	Disclosing Party
	 	1.16
	Dispute
	 	10.2.1
	Early Stage-Sublicensed Product
	 	4.2.3(a)
	Effective Date
	 	Recitals
	Expert
	 	10.2.2(a)
	Filing Party
	 	6.4.3
	Gilead Indemnitee
	 	8.3
	Indemnified Party
	 	8.2
	Indemnifying Party
	 	8.2
	Infringement
	 	6.5.1
	Infringement Notice
	 	6.5.1
	Minimum Acceptable Financial Terms
	 	3.6
	Non-Filing Party
	 	6.4.3
	Oncology Option
	 	3.7
	Oncology Option Notice
	 	3.7
	Oncology Option Termination Date
	 	3.7
	Party
	 	Recitals
	Parties
	 	Recitals
	Ribomic Patent Rights
	 	6.2
	Receiving Party
	 	1.16
	Required Jurisdictions
	 	6.4.2
	Ribomic
	 	Recitals
	ROFR Notice
	 	3.6

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

12

 

	 	 	 
	Definition	 	Section
	ROFR Response
	 	3.6
	Specific Diligence Obligations
	 	3.1.2(b)
	Sublicense Income Payments
	 	4.4.1
	Term
	 	9.1
	Third Party Negotiation Period
	 	3.6

2. GRANT OF RIGHTS

     2.1 Licenses.

          2.1.1 Grant of Rights to Ribomic.

               (a) Grant of License. Archemix hereby grants to Ribomic an exclusive, royalty-bearing
license, including the right to grant sublicenses in accordance with Section 2.1.1(c), under the
Licensed Patent Rights and Licensed Technology, to Develop, have Developed, make, have made, use,
have used, sell, offer for sale, distribute for sale, have sold, import, have imported, export and
have exported Licensed Products in the Territory, for any and all uses within the Field, subject to
the terms and conditions of this Agreement. For purposes of clarity, Ribomic shall have no rights
under this Agreement to use the SELEX Process and SELEX Technology, alone or with a Third Party,
except for the sole purpose of identifying and modifying Program Aptamers for use in the Field.

               (b) Negative Covenant. Ribomic is not granted the right to, and hereby covenants and
agrees that neither it nor its Affiliates will (i) use the SELEX Process or SELEX Technology (A) on
any Target that is not the Program Target and (B) except for the purpose of identifying or
modifying Program Aptamers and/or for the conduct by Ribomic of Permitted Ribomic Activities as
expressly permitted under this Agreement, (ii) research, develop, make, have made, use, have used,
sell, offer for sale, have sold, distribute for sale, import, have imported, export or have
exported Diagnostics or (iii) perform any research or development on Program Aptamers for any use
outside of the Field. Notwithstanding the foregoing, Ribomic shall not be restricted by this
Section 2.1.1(b) from engaging in any (i) Permitted Ribomic Activities or (ii) activity in which
Ribomic is permitted to engage pursuant to a license, sublicense or other right granted to Ribomic
in any agreement other than this Agreement (including, without limitation, the Existing License
Agreement) with respect to the SELEX Portfolio, the SELEX Process, SELEX Technology or Aptamers,
whether granted by Archemix, or any Third Party having the right to grant such license, sublicense
or other right. To the extent Ribomic or its Affiliates engages in any activities in violation of
the negative covenant set forth in this Section 2.1.1(b) during the Term and files any patent
applications or obtains any Patent Rights related to or arising out of such activities then,
without limiting any other remedy Archemix may have under this Agreement and without any further
action of either Party, Ribomic shall be deemed to have granted to Archemix, effective as of the
date of any such filing, an exclusive, fully-paid, perpetual, irrevocable, royalty-free license
under all such Patent Rights for any and all uses.

               (c) Right to Sublicense. Ribomic shall have the right to grant sublicenses to all or
any portion of its rights under the license granted pursuant to Section 2.1.1(a); provided, that,
(i) Archemix shall be notified of the grant of each such sublicense, (ii) each such sublicense
shall be subject to, and consistent with, the terms and conditions of this Agreement, (iii) each
such sublicense shall include the following provisions of this Agreement

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

13

 

(with appropriate modifications to account for the identities of the parties to such
sublicense): Sections 2.1.1(b) (Negative Covenant), 2.1.2(d) (Reversion of License Rights),
2.1.2(e) (Gilead-Archemix License Agreement), Section 3.5 (Notice of Certain Events), 6.6 (Effect
of Challenge) and 9.2.2 (Termination for Challenge), (iv) upon termination of this Agreement, any
such sublicense shall be considered a direct license from Archemix as provided in Section 9.3
hereof, and (v) Ribomic shall provide Archemix with a copy of each Sublicense Agreement within
thirty (30) days of execution.

               (d) Reversion of License Rights. Ribomic acknowledges and agrees that each of the URC
License Agreement and the Gilead-Archemix License Agreement provides that the Archemix rights in
the SELEX Process or the SELEX Technology and the SELEX Portfolio may revert to Gilead or ULEHI if
Archemix, its Affiliates and all assignees and sublicensees cease to exercise reasonable efforts to
develop the commercial applications of products and services utilizing the SELEX Process or the
SELEX Technology. Ribomic further acknowledges and agrees that the URC License Agreement provides
that in the event of any termination of the URC License Agreement, the license to SELEX granted to
Ribomic hereunder shall remain in full force and effect in accordance with Section 3.4 of the URC
License Agreement; provided, that, Ribomic is not then in breach of this Agreement and Ribomic
agrees to be bound to ULEHI as the licensor under the terms and conditions of this Agreement.
Archemix shall inform Ribomic of such event immediately after the Archemix rights revert to Gilead
or ULEHI.

               (e) Gilead-Archemix License Agreement. Ribomic acknowledges and agrees that the
Gilead-Archemix License Agreement provides that in the event of any termination of the
Gilead-Archemix License Agreement, the license to SELEX granted to Ribomic hereunder shall remain
in full force and effect in accordance with Section 2.3 of the Gilead-Archemix License Agreement;
provided, that, Ribomic agrees to be bound to Gilead as the licensor under the terms and conditions
of this Agreement; provided, that, if the termination of the Gilead-Archemix License Agreement
arises out of the action or inaction of Ribomic, Gilead, at its option, may terminate such license.
Archemix shall inform Ribomic of such event promptly after the Gilead-Archemix License Agreement is
terminated.

          2.1.2 Grant of Rights to Archemix.

               (a) Grant of License. Subject to the other terms of this Agreement, Ribomic hereby
grants to Archemix a non-exclusive, royalty-free, paid-up, perpetual, irrevocable, worldwide
license, with the right to grant sublicenses, under Ribomic SELEX Technology and Ribomic Patent
Rights (i) to research, develop, make, have made, use, have used, sell, offer for sale, have sold,
import, have imported, export, have exported, and commercialize Aptamers for any and all purposes,
and (ii) for any and all uses of the SELEX Process and SELEX Technology (the “Archemix
License”); provided, however, that the licenses in clause (i) and (ii) shall not apply to
Program Aptamers or include any specific aptamer sequences that are identified through the conduct
by Ribomic of the Permitted Ribomic Activities.

               (b) Covenant. Ribomic covenants and agrees to register the non-exclusive license
granted to Archemix under Section 2.1.2(a) under Japanese Patent No. 2,763,958 with the Japan
Patent Office as soon as practicable after the Effective Date and to provide Archemix with prompt
notice of such registration. Archemix shall reasonably cooperate

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

14

 

with Ribomic to assist in the preparation and execution of the registration and all formal
documents to effect such registration, at Ribomic’s sole cost and expense, if any.

     2.2 No Other Rights. Ribomic is not granted any rights to use or otherwise exploit
Licensed Patent Rights or Licensed Technology except as set forth in this Agreement and Archemix is
not granted any rights to use or otherwise exploit Ribomic SELEX Technology or Ribomic Patent
Rights except as set forth in this Agreement.

     2.3 Exclusivity; Additional Targets.

          2.3.1 Exclusivity.

               (a) Archemix Restrictions. During the Term, neither Archemix nor any of its
Affiliates will, alone or with a Third Party, conduct any activity, or grant any Third Party a
license to conduct any activity, for the purpose of researching, developing or commercializing any
Program Aptamer or Licensed Product in the Field in the Territory. Notwithstanding anything to the
contrary set forth in this Agreement, the restrictions set forth in this Section 2.3.1(a) shall not
apply to the conduct by Archemix or any of its Affiliates of Permitted Archemix Activities.

               (b) Ribomic Restrictions. During the period commencing on the Effective Date and
continuing until the later of the termination or expiration of this Agreement and the expiration of
the Full Royalty Term, neither Ribomic nor any of its Affiliates will, alone or with a Third Party,
conduct any activity or grant any Third Party a license to conduct any activity, for the purpose of
researching, developing or commercializing any aptamer other than a Program Aptamer for use in the
Field in the Territory as contemplated by this Agreement. Notwithstanding the above, Ribomic may
conduct the Permitted Ribomic Activities.

3. RESEARCH, DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS.

     3.1 Research, Development and Commercialization.

          3.1.1 Responsibility. From and after the Effective Date, Ribomic shall have full
control and authority over the research, Development and commercialization of Licensed Products in
the Field in the Territory, including, without limitation, (a) all pre-clinical research activities
(including any pharmaceutical development work on formulations or process development relating to
any Licensed Product), (b) all activities related to the conduct of human clinical trials relating
to any Licensed Product, (c) all activities relating to manufacture and supply of Licensed Products
(including all required process development and scale up work with respect thereto), (d) all
marketing, promotion, sales, distribution, import and export activities relating to any Licensed
Product, and (e) all activities relating to any regulatory filings, registrations, applications and
Regulatory Approvals relating to any of the foregoing. Ribomic shall own all data, results and all
other information arising from any such activities under this Agreement, including, without
limitation, all regulatory filings, registrations, applications and Regulatory Approvals relating
to Licensed Products, and all of the foregoing information, documentation and materials shall be
considered Confidential Information and Technology solely owned by Ribomic. All activities
relating to Development and commercialization of Licensed Products under this Agreement shall be
undertaken at Ribomic’s sole cost and expense,

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

15

 

except as otherwise expressly provided in this Agreement.

          3.1.2 Diligence.

               (a) General Diligence Obligations. Ribomic will exercise Commercially Reasonable
Efforts in Developing and commercializing Licensed Products in the Field and in undertaking
investigations and actions required to obtain Regulatory Approvals necessary to market such
Licensed Products in the Field in each of the United States, each of the E5 Countries and in Japan,
and in any other ex-United States markets, in addition to the E5 Countries and Japan, where Ribomic
determines, in the exercise of Commercially Reasonable Efforts, that it is commercially reasonable
to do so. In the event that Ribomic fails to use Commercially Reasonable Efforts as required
hereunder then, on a Licensed Product-by-Licensed Product and country–by-country basis as to such
Licensed Product in the United States or Japan and, with respect to any E5 Country, in all of the
E5 Countries, (i) Archemix may, in its sole discretion (A) terminate the licenses granted under
Section 2.1.1 of this Agreement for breach under Section 9.2.3 below or (B) convert the licenses
granted under Section 2.1.1 of this Agreement from exclusive licenses to non-exclusive licenses, in
either case only as such licenses apply to such Licensed Product in such country(ies) and, with
respect to any E5 Country, in all of the E5 Countries, and (ii) to the extent Archemix exercises
its rights under Section 3.1.2(a)(i)(A) or (B) with respect to a Licensed Product, Archemix’s
exclusivity obligations under Section 2.3.1(a) shall terminate with respect to such Licensed
Product in such country(ies).

               (b) Specific Diligence Obligations. Without limiting the generality of the provision
of Section 3.1.2(a) above, Ribomic hereby agrees that it will achieve the specific milestones set
forth in Schedule 2 attached hereto within the timelines set forth on such Schedule
2 (such obligations, the “Specific Diligence Obligations”). In the event that Ribomic
fails to meet any of the Specific Diligence Obligations set forth in this Section 3.1.2(b) within
the applicable timeline, but is otherwise in compliance with the provisions of Section 3.1.2(a)
during the applicable diligence period specified above, then Archemix and Ribomic will negotiate in
good faith an extension of the applicable milestone deadline for a period not to exceed [***] days
from the applicable deadline date. If the Parties are unable to agree on such an extension within
such negotiation period, then on a Licensed Product-by-Licensed Product and country-by-country
basis as to such Licensed Product in such country and, with respect to any E5 Country, in all of
the E5 Countries, (i) Archemix may, in its sole discretion (A) terminate the licenses granted under
Section 2.1.1 of this Agreement for breach under Section 9.2.3 below or (B) convert the licenses
granted under Section 2.1.1 of this Agreement from exclusive licenses to non-exclusive licenses, in
either case only as such licenses apply to such Licensed Product in such country(ies) and, with
respect to any E5 Country, in all of the E5 Countries, and (ii) to the extent Archemix exercises
its rights under Section 3.1.2(b)(i)(A) or (B) with respect to a Licensed Product, Archemix’s
exclusivity obligations under Section 2.3.1(a) shall terminate with respect to such Licensed
Product in such country(ies). Archemix may waive any specific milestone diligence requirement on a
case by base basis.

     3.2 Development Plan. Ribomic shall submit to Archemix, for its review, a summary
development plan (“Development Plan”) for each Licensed Product that Ribomic, its
Affiliates and/or Sublicensees intend to Develop and commercialize in the Field for each Indication
which shall be attached hereto as Exhibit C and shall submit an update to such Development
Plan(s) on each anniversary of the Effective Date.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

16

 

     3.3 Progress Reports. Ribomic shall provide Archemix with written reports every [***]
months during the Term that describes in reasonable detail its progress with respect to its SELEX
efforts and Development activities which shall include, at minimum, information reasonably
sufficient to enable Archemix to satisfy its reporting obligations to Gilead under the
Gilead-Archemix License Agreement with respect to this Agreement and to assess the progress made by
Ribomic toward meeting the diligence obligations of Section 3.1 above.

     3.4 Diligence Committee. To facilitate the providing of progress reports by Ribomic
with respect to the research and Development of Licensed Products contemplated by this Agreement,
at Archemix’s sole option and request the Parties will establish a Diligence Committee (the
“DC”), which will be comprised of equal numbers of representatives of each of the Parties.
The DC will meet on dates mutually agreed to by the Parties not more than twice per Calendar Year,
in person or by teleconference which, if in person, shall alternate between the offices of
Cambridge, Massachusetts and Tokyo, Japan.  Intellectual property representatives of each Party may
be invited to participate in DC meetings and such meetings will provide a forum to discuss any
patent prosecution and enforcement issues that arise under this Agreement.   The DC may be
established at any time within [***] years of the Effective Date and if established, the DC will
terminate [***] years after the Effective Date, subject to extension by mutual written agreement of
the Parties. Each Party will be responsible for the costs and expenses incurred by its
representative in participating on the DC. Notwithstanding anything to the contrary in this
Section 3.4, the DC shall have no authority to make any decisions binding on the Parties with
respect to either Party’s performance under this Agreement.

     3.5 Notice of Certain Events. In addition to the progress reports required pursuant
to Section 3.3 above, Ribomic shall provide Archemix with written notice within [***] days of the
occurrence of (a) the [***] in each country, (b) the Completion of each [***], [***] and [***] of a
Licensed Product, and the final reports thereof, (c) each milestone set forth in Section 4.2 below,
(d) any Regulatory Approval and Commercialization Regulatory Approval in each country, (e) any
other material event other than as set forth in the foregoing clauses (a)-(d) related to the
Development or commercialization of Licensed Products, and (f) any Adverse Event or product
complaint information relating to Licensed Products as compiled and prepared by Ribomic in the
normal course of business in connection with the Development, commercialization or sale of any
Licensed Product, within time frames consistent with reporting obligations under Applicable Laws.
Archemix may provide such Adverse Event information (i) to the extent reasonably necessary to
licensees of Archemix that are researching, developing or commercializing Aptamers for therapeutic
purposes and have agreed to maintain the confidentiality thereof and (ii) to Third Parties as
required by Applicable Laws.

     3.6 Right of First Refusal. In the event that Ribomic at any time during the ROFR
Period determines to enter into an agreement with a Third Party to [***] and/or [***] any [***]
that includes [***] and [***] that are [***] Dollars ($[***]) (the “Minimum Acceptable
Financial Terms”), it shall provide written notice of same to Archemix, which notice shall
include a copy of the term sheet or letter of intent or other written evidence of the proposed
terms of such transaction (the “ROFR Notice”). Archemix shall have [***] days from the
date of the ROFR Notice to provide a written response (the “ROFR Response”) as to whether
or not it wishes to participate in the Development and commercialization of such Licensed Product
on the terms set forth in the ROFR Notice. If the ROFR Response is not provided by Archemix within
the [***] day response period, Ribomic shall thereafter have the right to negotiate and enter into

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

17

 

an agreement with such Third Party with respect to the [***] and/or[***] of such [***] on the
terms set forth in the ROFR Notice for a period of up to [***] days (the “Third Party
Negotiation Period”); provided, that, if Ribomic and such Third Party do not enter into such
agreement on or before the expiration of the Third Party Negotiation Period, the [***] shall once
again be subject to this Section 3.6. If the ROFR Response states that Archemix wishes to enter
into negotiations with Ribomic, the Parties shall negotiate in good faith for, and complete such
negotiations within, a period of up to [***] days from the date of the ROFR Response with respect
to the terms and conditions applicable to the [***] and/or [***] by Archemix of such Licensed
Product on the terms set forth in the ROFR Notice. In the event the Parties fail to execute and
deliver the agreement within the [***] day period, the Parties shall (a) use reasonable efforts to
complete such negotiations and to execute and deliver the agreement or amendment as soon as
possible after such [***] day period and (b) without limiting the generality of the foregoing,
after the expiration of such [***] day period, each produce a list of issues on which they have
failed to reach agreement and submit its list to be resolved in accordance with Section 10.2.2.
Notwithstanding the foregoing, the Parties hereby acknowledge and agree that once Ribomic has
successfully concluded an agreement with a Third Party for any or all Indications of a Licensed
Product meeting the Minimum Acceptable Financial Terms, the ROFR Period shall automatically
terminate and, thereafter, Archemix will cease to have the Right of First Refusal set forth herein
above for subsequent agreements for [***] involving the [***] of any Licensed Product.

     3.7 Oncology Opt-In Right. Archemix shall have the option (the “Oncology
Option”), in its sole discretion, to jointly Develop and commercialize any Licensed Product for
oncology Indications on a Major Market Country-by-Major Market Country basis by providing written
notice (the “Oncology Option Notice”) at any time during the period commencing on the
Effective Date and continuing until the earlier of the Initiation of the first Phase IIa Clinical
Trial with respect to that Licensed Product and the execution by Ribomic of a Sublicense Agreement
which includes the grant to a Third Party of the right to Develop and commercialize any Licensed
Product in a Major Market Country (the “Oncology Option Termination Date”), which notice
shall identify the Licensed Product which Archemix elects to jointly Develop and commercialize. In
connection therewith, Ribomic shall provide Archemix with written notice not less than [***] days
prior to the expected occurrence of any Oncology Option Termination Date. If Archemix exercises
the Oncology Option with respect to any Licensed Product, the Parties shall negotiate an agreement
and/or an amendment to this Agreement and the terms applicable thereto in good faith and with
sufficient diligence as is required to execute and deliver the agreement or amendment within [***]
days after Archemix provides the Oncology Option Notice. In the event the Parties fail to execute
and deliver the agreement or amendment within the [***] day period, the Parties shall (a) use
reasonable efforts to complete such negotiations and to execute and deliver the agreement or
amendment as soon as possible after such [***] day period and (b) without limiting the generality
of the foregoing, after the expiration of such [***] day period, each produce a list of issues on
which they have failed to reach agreement and submit its list to be resolved in accordance with
Section 10.2.2. The Parties hereby acknowledge and agree that in the event Ribomic is in
compliance with the notice provisions of this Section 3.7 and enters into a Sublicense Agreement
with a Third Party which includes the grant to such Third Party of the right to Develop and
commercialize any Licensed Product in the applicable Major Market Country(ies), the Oncology Option
will automatically terminate and thereafter be void in the applicable Major Market Country(ies).

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

18

 

4. PAYMENTS AND ROYALTIES

     4.1 Technology Access and License Fee. In consideration for the rights granted to
Ribomic hereunder, Ribomic hereby agrees to pay Archemix an upfront technology access and license
fee in the amount of One Million Dollars (U.S. $1,000,000), payable within thirty (30) days of the
Effective Date by wire transfer of immediately available funds, which payment shall be
non-refundable and non-creditable.

     4.2 Milestone Payments.

          4.2.1 All Licensed Products. Ribomic shall make the corresponding non-refundable,
non-creditable payments to Archemix by wire transfer according to instructions that Archemix shall
provide within [***] days of the occurrence of the following milestone events for a Licensed
Product Developed by Ribomic or any Affiliate or Sublicensee of Ribomic:

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 

          4.2.2 Licensed Products That Are Not Early-Stage Sublicensed Products. In addition to
the milestone payments described in Section 4.2.1 above, Ribomic shall make the corresponding
non-refundable, non-creditable payments to Archemix by wire transfer according to instructions that
Archemix shall provide within [***] days of the occurrence of the following milestone events for
any Licensed Product that is not an Early-Stage Sublicensed Product (including, without limitation,
any Licensed Product that is Developed under a Late Stage Sublicense Agreement) (a “Covered
Licensed Product”):

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

19

 

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 

     For purposes of clarity, (i) any Sublicense Agreement that includes a Covered Licensed Product
shall be considered a Late Stage Sublicense Agreement regardless of whether other Licensed Products
that are not Covered Licensed Products are included in such Sublicense Agreement and (ii) all
Licensed Products included in such Late Stage Sublicense Agreement shall be subject to Section
4.2.2 and not Section 4.2.3.

          4.2.3 Early Stage-Sublicensed Products.

               (a) In the event Ribomic enters into an Early-Stage Sublicense Agreement, then, in addition to
the milestone payments contemplated by Section 4.2.1, but in lieu of making any milestone payments
for the milestone events contemplated by Section 4.2.2, Ribomic shall make the corresponding
non-refundable, non-creditable payments to Archemix by wire transfer according to instructions that
Archemix shall provide within [***] days of the occurrence of the following milestone events for
any Licensed Product that is Developed under such Early-Stage Sublicense Agreement (an “Early
Stage-Sublicensed Product”):

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 

               (b) Adjustment to Milestone Payments. In the event that any Early Stage Sublicense
Agreement provides for the payment to Ribomic of aggregate Sublicense Income in an amount in excess
of [***] Dollars (US $[***]), the aggregate milestone payments included in Section 4.2.3(a) shall
be increased by [***] percent ([***]%) of the amount by which such aggregate Sublicense Income
exceeds [***] Dollars (US $[***]), which increase shall be apportioned equally across each of the
Milestone Events set forth in Section 4.2.3(a). By way of example, if Ribomic enters into an Early
Stage Sublicense Agreement that provides for the payment of, and/or otherwise receives, aggregate
Sublicense Income in the amount of [***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

20

 

Dollars (US $[***]), (i) the aggregate Milestone Payments in Section 4.2.3(a) will by
increased by [***] Dollars (US $[***]) ([***] percent ([***]%) of [***] Dollars (US $[***])), (ii)
the Milestone Payments due and payable in Japan pursuant to Section 4.2.3(a) shall be increased in
the aggregate by [***] Dollars (US $[***]), (iii) the Milestone Payments due and payable in the
United States shall be increased in the aggregate by [***] Dollars (US $[***]) and (iv) the
Milestone Payments due and payable in the E5 Countries shall be increased in the aggregate by [***]
Dollars (US $[***]).

          4.2.4 Skipped Milestones; Crediting of Certain Milestone Payments.

               (a) Skipped Milestones. If at the time any given milestone payment set forth in
Section 4.2 is due and one or more preceding milestone payments for logically antecedent milestones
have not been paid, then such unpaid antecedent milestone payments shall be paid at such time as
well. For example, if at the time an [***] milestone payment is due for a Licensed Product, an
[***] milestone payment has not been paid for a Licensed Product, then such [***] milestone payment
shall be paid at such time as well.

               (b) Crediting of Certain Milestone Payments. In the event that Ribomic enters into
one or more Sublicense Agreements covering a Licensed Product, all Milestone Payments for Milestone
Events achieved by Ribomic and/or the Sublicensee with respect to that Licensed Product on and
after the effective date of the Sublicense Agreement shall be fully creditable against Sublicense
Income Payments payable by Ribomic with respect to that Sublicense Agreement.

               (c) Payable Once Per Program Target. All of the milestone payments set forth in
Section 4.2 shall be payable only once per Program Target, regardless of how many Licensed Products
achieve such milestones and no milestone payment already made for a Licensed Product shall be paid
for any subsequent Licensed Product or any subsequent Indication for the same Licensed Product with
respect to said particular milestone.

          4.2.5 Determination that Payments are Due. In the event that Archemix believes any
milestone payment is due pursuant to Section 4.2.1, 4.2.2 and/or 4.2.3, it shall so notify Ribomic
and shall provide to Ribomic the data and information supporting its belief that the conditions for
payment have been achieved. If Ribomic disputes that such milestone payment is due, either Party
may submit such dispute for resolution pursuant to the provisions of Section 10.2.2.

     4.3 Payment of Royalties; Royalty Rates. 

          4.3.1 Royalty Rates in Defined Territory. For each Licensed Product, Ribomic shall
pay Archemix a royalty based on Annual Net Sales of such Licensed Product in each Calendar Year (or
partial Calendar Year) in any country in the Defined Territory commencing with the First Commercial
Sale of such Licensed Product in any country in the Defined Territory and ending upon the last day
of the last Royalty Term for such Licensed Product, at the following rates:

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

21

 

	 	 	 	 	 	 	 	 	 
	 	 	Full Royalty Net	 	Partial Royalty
	 	 	Sales	 	Net Sales
	Annual Net Sales	 	Royalty Rate (%)
	Up to $[***]
	 	 	[***]	%	 	 	[***]	%
	Above $[***] and up to $[***]
	 	 	[***]	%	 	 	[***]	%
	Above $[***] and up to $[***]
	 	 	[***]	%	 	 	[***]	%
	Above $[***]
	 	 	[***]	%	 	 	[***]	%

          4.3.2 Royalty Rates Outside Defined Territory. For each Licensed Product, Ribomic
shall pay Archemix a royalty based on Annual Net Sales of such Licensed Product in each Calendar
Year (or partial Calendar Year) in any country outside the Defined Territory commencing with the
First Commercial Sale of such Licensed Product in any country outside the Defined Territory and
ending upon the last day of the last Royalty Term for such Licensed Product, at a royalty rate
equal to [***] percent ([***]%) for Full Royalty Net Sales and [***] percent ([***]%) for Partial
Royalty Net Sales.

          4.3.3 Acknowledgements. Ribomic recognizes and acknowledges that each of the
following, separately and together, has substantial economic benefit to Ribomic: (a) the licenses
granted to Ribomic hereunder with respect to Licensed Technology that are not within the claims of
any Patent Rights Controlled by Archemix; (b) the licenses granted to Ribomic under Patent
Rights Controlled by Archemix; (c) the restrictions on Archemix pursuant to Section 2.3.1(a); and
(d) the “head start” afforded to Ribomic by each of the foregoing. The Parties agree that the
royalty rates set forth in Sections 4.3.1 and 4.3.2 reflect an efficient and reasonable blended
allocation of the royalty amounts to be paid by Ribomic to Archemix in its totality.

          4.3.4 Royalty Reductions. In the event that a Third Party sells an aptamer product
that binds to the Program Target (a “Third Party Product”) in a country in which a Program
Aptamer or Licensed Product is then being sold by Ribomic and such Third Party Product is not
covered by a Valid Claim under the Licensed Patent Rights in such country, then, during the period
in which sales of the Third Party Product are equal to at least [***] percent ([***]%) of Ribomic’s
volume-based market share of the Program Aptamer or Licensed Product in such country (as measured
by prescriptions or other similar information available in such country) all applicable royalties
in effect with respect to such Program Aptamer or Licensed Product in such country as specified in
Section 4.3.1 shall be reduced by [***] percent ([***]%). Notwithstanding the foregoing, Ribomic’s
obligation to pay royalties at the full royalty rates shall be reinstated on the first day of the
Calendar Quarter immediately following the Calendar Quarter in which sales of such Third Party
Product account for less than [***] percent ([***]%) of Ribomic’s volume-based market share in such
country.

     4.4 Sublicense Income.

          4.4.1 Sublicense Income Payments. In consideration for the rights granted to Ribomic
hereunder, Ribomic shall pay Archemix a percentage of all Sublicense Income received by Ribomic
under Sublicense Agreements with respect to Licensed Products equal to the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

22

 

Applicable Sublicense Income Rate (“Sublicense Income Payments”).

          4.4.2 Crediting of Milestones. Notwithstanding anything to the contrary in this
Agreement, Ribomic shall have the right to credit any Milestone Payment it makes with respect to a
Licensed Product on and after the date of execution of any Sublicense Agreement against Sublicense
Income Payments due and payable to Archemix with respect to that Licensed Product under that
Sublicense Agreement.

     4.5 Payment Terms.

          4.5.1 Payment of Royalties and Sublicense Income Payments. Unless otherwise expressly
provided, Ribomic shall make any royalty and Sublicense Income payments owed to Archemix hereunder
in arrears, within [***] days from the end of the Calendar Quarter in which such payment accrues.
For purposes of determining when a sale of any Licensed Product occurs under this Agreement, the
sale shall be deemed to occur on the date the invoice is provided by Ribomic, its Affiliates or
Sublicensees. Each royalty payment shall be accompanied by a report for each country in the
Territory in which sales of Licensed Products occurred in the Calendar Quarter covered by such
statement, specifying: (a) the gross sales (if available) and Net Sales in each country’s currency;
(b) the applicable royalty rate under this Agreement; (c) an accounting of deductions taken in the
calculation of Net Sales made in the United States and in any other country in which such
accounting is reasonably available; (d) the applicable exchange rate to convert from each currency
other than United States dollars to United States dollars under this Section 4.5; and (e) the
royalties payable in United States dollars. Each Sublicense Income Payment will be accompanied by
a report for each country in the Territory in which Sublicense Income is received in the Calendar
Quarter covered by such statement, specifying: (a) all consideration and payments received by
Archemix under such Sublicense Agreement; (b) the Applicable Sublicense Income Rate; and (c) an
accounting of any deductions taken in the calculation of the amount of the Sublicense Income.

          4.5.2 Overdue Payments. Subject to the other terms of this Agreement, any payments
not paid within the time period set forth in this Article 4 shall bear interest at a rate of [***]
percent ([***]%) per month from the due date until paid in full; provided, that, in no event shall
said annual rate exceed the maximum interest rate permitted by law in regard to such payments. Any
such overdue royalty or milestone payment shall, when made, be accompanied by, and credited first
to, all interest so accrued. Said interest and the payment and acceptance thereof shall not negate
or waive the right of Archemix to any other remedy, legal or equitable, to which it may be entitled
because of the delinquency of the payment.

          4.5.3 Accounting. All payments hereunder shall be made in the United States in United
States dollars. Conversion of foreign currency to United States dollars shall be made at the
conversion rate existing in the United States (as reported in The Wall Street Journal) on the last
business day of the applicable Calendar Quarter. If The Wall Street Journal ceases to be published
or if the Parties agree otherwise, then the rate of exchange to be used shall be that reported in
such other business publication of national circulation in the United States as the Parties
reasonably agree.

          4.5.4 Withholding Taxes; Restrictions on Payment. All payments hereunder

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

23

 

shall be made free and clear of any taxes, duties, levies, fees or charges, except for
withholding taxes (to the extent applicable), Ribomic shall make any applicable withholding
payments due on behalf of Archemix and shall provide Archemix upon request with such written
documentation regarding any such payment available to Ribomic relating to an application by
Archemix for a foreign tax credit for such payment with the United States Internal Revenue Service.

     4.6 Records Retention; Review.

          4.6.1 Records; Audit. Ribomic and its Affiliates and Sublicensees shall keep and
maintain for [***] years from the date of each payment of royalties and Sublicense Income Payments
hereunder complete and accurate records of gross sales and Net Sales by Ribomic and its Affiliates
and Sublicensees of each Licensed Product, in sufficient detail to allow royalty payments and
Sublicense Income Payments to be determined accurately. Archemix shall have the right for a period
of [***] years after receiving any such royalty payment and Sublicense Income Payments to appoint
at its expense an independent certified public accountant reasonably acceptable to Ribomic to audit
the relevant records of Ribomic and its Affiliates and Sublicensees to verify that the amount of
such payment was correctly determined. Ribomic and its Affiliates and Sublicensees shall each make
its records available for audit by such independent certified public accountant during regular
business hours at such place or places where such records are customarily kept, upon [***] days
written notice from Archemix, solely to verify that royalty payments and Sublicense Income Payments
hereunder were correctly determined. Such audit right shall not be exercised by Archemix more than
once in any Calendar Year or more than once with respect to sales of a particular Licensed Product
in a particular period. All records made available for audit shall be deemed to be Confidential
Information of Ribomic or its Affiliates or Sublicensees, as applicable. The results of each
audit, if any, shall be binding on both Parties. In the event there was an underpayment by Ribomic
hereunder, Ribomic shall promptly (but in any event no later than [***] days after Ribomic’s
receipt of the report so concluding) make payment to Archemix of any shortfall. Archemix shall
bear the full cost of such audit unless such audit discloses an underreporting by Ribomic of more
than [***] percent ([***]%) of the aggregate amount of royalty payments and/or Sublicense Income
Payments payable in any Calendar Year, in which case Ribomic shall reimburse Archemix for [***]
costs incurred by Archemix in connection with such audit.

          4.6.2 Other Parties. Ribomic shall include in any agreement with its Affiliates or
Sublicensees terms requiring such party to retain records as required in this Section 4.6 and to
permit Archemix to audit such records as required by this Section 4.6.

5. TREATMENT OF CONFIDENTIAL INFORMATION

     5.1 Confidentiality Obligations. Archemix and Ribomic each recognizes that the other
Party’s Confidential Information constitutes highly valuable assets of such other Party. Archemix
and Ribomic each agrees that, subject to the remainder of this Article 5, it will not disclose, and
will cause its Affiliates and sublicensees not to disclose, any Confidential Information of the
other Party and it will not use, and will cause its Affiliates and sublicensees not to use, any
Confidential Information of the other Party except as expressly permitted hereunder; provided,
that, such obligations shall apply during the Term and for an additional [***] years thereafter.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

24

 

     5.2 Limited Disclosure and Use. Archemix and Ribomic each agrees that disclosure of
its Confidential Information may be made by the other Party to any employee, consultant,
contractor, Affiliate or Sublicensee of such other Party to enable such other Party to exercise its
rights or to carry out its responsibilities under this Agreement; provided, that, any such
disclosure or transfer shall only be made to Persons who are bound by written obligations as
described in Section 5.3. In addition, Archemix and Ribomic each agrees that the other Party may
disclose its Confidential Information (a) on a need-to-know basis to such other Party’s legal and
financial advisors, (b) as reasonably necessary in connection with an actual or potential (i)
permitted sublicense of such other Party’s rights hereunder, (ii) debt or equity financing of such
other Party or (iii) transfer or sale of all or substantially all of such Party’s assets or
business or in the event of its merger, consolidation, change in control or similar transaction,
and (b) for any other purpose with the other Party’s written consent, not to be unreasonably
withheld, conditioned or delayed. In addition, each Party agrees that the other Party may disclose
such Party’s Confidential Information as required by Applicable Laws; provided, that, in the case
of any such disclosure, the disclosing Party shall (1) if practicable, provide the other Party with
reasonable advance notice of and an opportunity to comment on any such required disclosure and (2)
if requested by the other Party, cooperate in all reasonable respects with the other Party’s
efforts to obtain confidential treatment or a protective order with respect to any such disclosure,
at the other Party’s expense.

     5.3 Employees and Consultants. Ribomic and Archemix each hereby represents that all
of its employees, consultants and contractors, and all of the employees, consultants and
contractors of its Affiliates and sublicensees (including, without limitation, Sublicensees), who
have access to Confidential Information of the other Party are or will, prior to their
participation or access, be bound by written obligations to maintain such Confidential Information
in confidence and not to use such information except as expressly permitted hereunder. Each Party
agrees to use, and to cause its Affiliates and sublicensees (including, without limitation,
Sublicensees) to use, reasonable efforts to enforce such obligations.

     5.4 Publicity. The Parties acknowledge and agree that (a) the terms of this Agreement
constitute Confidential Information of each Party and may only be disclosed (i) as permitted by
Section 5.2, and (ii) to investment bankers, investors, and potential investors, lenders and
potential lenders and other sources and other potential sources of financing, licensees and
potential licensees, acquirers or merger partners and potential acquirers or merger partners of
such Party, and, with respect to Archemix, to Gilead and University License Equity Holdings, Inc.;
and (b) a copy of this Agreement may be filed by either Party with the Securities and Exchange
Commission if such filing is required by Applicable Laws; provided, that, in connection with any
such filing, such Party shall endeavor to obtain confidential treatment of economic and trade
secret information, and shall provide the other Party with the proposed confidential treatment
request with reasonable time for such other Party to provide comments, which comments shall be
reasonably considered by the filing Party. Notwithstanding anything to the contrary in Section
5.1, except as required by Applicable Laws, neither Party shall issue a press or news release or
make any similar public announcement related to this Agreement without the prior written consent of
the other Party.

6. INTELLECTUAL PROPERTY RIGHTS AND PROVISIONS

     6.1 Licensed Technology; Licensed Patent Rights. Archemix shall have sole and

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

25

 

exclusive ownership of all right, title and interest on a worldwide basis in and to any and
all Licensed Technology and Licensed Patent Rights.

     6.2 Ribomic SELEX Patent Rights. Ribomic shall have sole and exclusive ownership of
all right, title and interest on a worldwide basis in and to any and all Patent Rights arising out
of the practice by Ribomic of the license pursuant to Section 2.1.1(a) (“Ribomic Patent
Rights”).

     6.3 Joint Technology; Joint Patent Rights. Ribomic and Archemix shall jointly own all
Joint Technology and Joint Patent Rights. Notwithstanding anything to the contrary contained in
this Agreement or under Applicable Laws, except to the extent exclusively licensed to one Party
under this Agreement, the Parties hereby agree that either Party may use or license or sublicense
to Affiliates or Third Parties all or any portion of its interest in Joint Technology, Joint Patent
Rights or jointly owned Confidential Information or Proprietary Materials for any purposes without
the prior written consent of the other Party, without restriction and without the obligation to
provide compensation to the other Party, except as otherwise provided under this Agreement.

     6.4 Prosecution of Patent Rights.

          6.4.1 Licensed Patent Rights. Archemix, at its sole expense and acting through patent
counsel or agents of its choice, shall be solely responsible for the preparation, filing,
prosecution and maintenance of the Licensed Patent Rights.

          6.4.2 Ribomic SELEX Patent Rights. Ribomic, its Affiliates and/or any Sublicensee, as
applicable, at its sole expense and acting through patent counsel or agents of its choice, shall
have the sole responsibility and obligation for the preparation, filing, prosecution and
maintenance of the Ribomic SELEX Patent Rights in the countries listed on Schedule 3 (the
“Required Jurisdictions”). In the event that Ribomic and/or any Sublicensee, as
applicable, determines not to file or to abandon any of the Ribomic SELEX Patent Rights in any of
the Required Jurisdictions, Ribomic shall notify Archemix sufficiently in advance so that Archemix
can, without any loss of rights, and Archemix shall have the right to, file, prosecute and maintain
such Ribomic SELEX Patent Rights in Ribomic’s name at Archemix’s expense in such Required
Jurisdictions.

          6.4.3 Joint Patent Rights. Unless the Parties otherwise agree, each Party, acting
through patent counsel or agents of its choice, shall be jointly responsible for the preparation,
filing, prosecution and maintenance of all Joint Patent Rights as follows: (a) Ribomic shall be
responsible for the preparation, filing, prosecution and maintenance of any such claims that
specifically claim any Program Aptamer; (b) Archemix shall be responsible for the preparation,
filing, prosecution and maintenance of any such claims that do not specifically claim any Program
Aptamer; (c) the Parties shall discuss in good faith whether and how to pursue those claims for
which they have primary responsibility under this Section 6.4.3 in separate patent applications;
(d) each Party that has responsibility for filing and prosecuting any Patent Rights under this
Section 6.4.3 (a “Filing Party”) shall provide the other party (the “Non-Filing
Party”) and its patent counsel with an opportunity to consult with the Filing Party and its
patent counsel regarding the filing and contents of any application, amendment, submission or
response filed pursuant to this Section 6.4.3; and (e) each Party shall be responsible for all
expenses

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

26

 

incurred by it for the preparation, filing prosecution and maintenance of any Joint Patent
Rights for which it has primary responsibility pursuant to this Section 6.4.3. The Filing Party
shall (a) regularly provide the Non-Filing Party with copies of all patent applications filed
hereunder for Joint Patent Rights and other material submissions and correspondence with the patent
offices, in sufficient time to allow for review and comment by the Non-Filing Party; and (b)
provide the Non-Filing Party and its patent counsel with an opportunity to consult with the Filing
Party and its patent counsel regarding the filing and contents of any such application, amendment,
submission or response, and the advice and suggestions of the Non-Filing Party and its patent
counsel shall be taken into consideration in good faith by such Filing Party and its patent counsel
in connection with such filing. Each Filing Party shall pursue in good faith all reasonable claims
and take such other reasonable actions, as may be requested by the Non-Filing Party in the
prosecution of any Joint Patent Rights under this Section 6.4.3; provided, however, if the Filing
Party incurs any additional expense as a result of any such request, the Non-Filing Party shall be
responsible for the cost and expenses of pursuing any such additional claim or taking such other
activities.

     6.5 Infringement.

          6.5.1 Notice. In the event that during the Term either Party becomes aware of any
possible infringement of any Licensed Patent Rights, Ribomic SELEX Patent Rights or Joint Patent
Rights, including the submission by any Third Party of an abbreviated new drug application under
the Hatch-Waxman Act or its equivalent outside the United States for a generic product (each, an
“Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”).

          6.5.2 Infringement of Licensed Patent Rights. Archemix shall have the sole right, but
not the obligation, in its sole discretion, at its own expense and with legal counsel of its own
choice, to bring suit (or take other appropriate legal action) against any actual, alleged or
threatened Infringement of the Licensed Patent Rights.

          6.5.3 Infringement of Ribomic SELEX Patent Rights. Ribomic and/or any Sublicensee, as
applicable, shall have the first right, at its own expense and with legal counsel of its own
choice, to bring suit (or take other appropriate legal action) against any actual, alleged or
threatened Infringement of the Ribomic SELEX Patent Rights. Archemix shall have the right, at its
own expense, to be represented in any such action by Ribomic by counsel of Archemix’s own choice;
provided, that, under no circumstances shall the foregoing affect the right of
Ribomic to control the suit as described in the first sentence of this Section 6.5.3. If Ribomic
and/or any such Sublicensee, as applicable, does not file any action or proceeding against any such
Infringement within [***] months (or [***] days in the case of an Infringement resulting from the
submission by any Third Party of an abbreviated new drug application under the Hatch-Waxman Act or
its equivalent outside the United States) after the later of (i) Ribomic’s notice to Archemix under
Section 6.5.1 above, (ii) Archemix’s notice to Ribomic under Section 6.5.1 above or (iii) a written
request from Archemix to take action with respect to such Infringement, then Archemix shall have
the right (but not the obligation), at its own expense, to bring suit (or take other appropriate
legal action) against such actual, alleged or threatened infringement, with legal counsel of its
own choice. If a Party brings any such action or proceeding hereunder, the other Party agrees to
be joined as party plaintiff if necessary to prosecute such action or

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

27

 

proceeding, and to give the Party bringing such action or proceeding reasonable assistance and
authority to file and prosecute the suit; provided, that, neither Party shall be required to
transfer any right, title or interest in or to any property to the other Party or any Third Party
to confer standing on a Party hereunder. Any damages, monetary awards or other amounts recovered,
whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken
under this Section 6.5.3, shall belong to Ribomic and/or any Sublicensee, as applicable (if it
brings such action) or Archemix (if it brings such action).

          6.5.4 Infringement of Joint Patent Rights. In the event of an Infringement of a Joint
Patent Right, the Parties shall enter into good faith discussions as to whether and how to
eliminate the Infringement. Each Party shall bear [***] of the cost of any action, suit
or proceeding instituted under this Section 6.5.4 and [***] of all amounts recovered shall
be received by each Party; provided, that, if the Parties are unable to determine whether and how
to institute an action, suit or proceeding for Infringement of any such Joint Patent Right, either
Party shall have the right to prosecute such Infringement, in which event that Party shall bear [***] and be entitled to retain [***]. Each Party shall have the
right to be represented by counsel of its own selection in any action, suit or proceeding
instituted under this Section 6.5.4 by the other Party. If a Party lacks standing and the other
Party has standing to bring any such action, suit or proceeding, then the Party with standing shall
bring such suit at the request and expense of the other Party.

     6.6 Effect of Challenge. In further consideration of Archemix’s grant of the licenses
hereunder and except to the extent the following is unenforceable under the Applicable Laws of a
particular jurisdiction where a patent application within the Licensed Patent Rights is pending or
a patent within the Licensed Patent Rights issued, in the event that Ribomic, its Affiliates and/or
Sublicensees during the Full Royalty Term (a) determines to initiate a Challenge or Ribomic, its
Affiliates and/or Sublicensees determines to assist a Third Party in initiating a Challenge,
Ribomic will provide written notice to Archemix at least [***] days prior thereto, which notice
will include an identification of all prior art it believes invalidates any claim of the Licensed
Patent Rights; and (b) initiates a Challenge or assists a Third Party in initiating a Challenge,
(i) the exclusive license granted by Archemix to Ribomic hereunder shall, at the option of the
Archemix and upon written notice to Ribomic, be converted into non-exclusive licenses as of the
date of such notice, (ii) during the pendency of such Challenge, the royalty rates set forth in
Section 4.3 shall be increased by an additional [***] percentage points in the Territory during the
Full Royalty Term (i.e., a [***]% royalty rate shall be increased to [***]%) commencing on the date
of such initiation, (iii) should the outcome of such Challenge determine that any claim of the
Licensed Patent Rights that is the subject of the Challenge is valid or enforceable, the royalty
rates set forth in Section 4.3 shall be increased by an additional five percentage points in the
Territory during the Full Royalty Term (i.e., a [***]% royalty rate shall be increased to [***]%)
on condition that the non-exclusive license shall revert to the exclusive license as of the date of
such decision and (iv) should the outcome of any Challenge determine no claim of the Licensed
Patent Rights is valid or enforceable in a country, Ribomic, its Affiliates and/or Sublicensees
shall continue to pay royalties based on Net Sales of Licensed Products sold in such country at the
rate of [***] percent ([***]%) until the last day of the Royalty Term for such Licensed Product.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

28

 

7. REPRESENTATIONS AND WARRANTIES; COVENANT REGARDING THIRD PARTY AGREEMENTS

     7.1 Mutual Representations and Warranties. Archemix and Ribomic each represents and
warrants to the other, as of the Effective Date, as follows:

          7.1.1 Organization. It is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, and has all requisite power and
authority, corporate or otherwise, to execute, deliver and perform this Agreement.

          7.1.2 Authorization. The execution and delivery of this Agreement and the performance
by it of the transactions contemplated hereby have been duly authorized by all necessary corporate
action and will not violate (a) such Party’s certificate of incorporation or bylaws, (b) any
agreement, instrument or contractual obligation to which such Party is bound in any material
respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment, injunction,
decree, determination or award of any court or governmental agency presently in effect applicable
to such Party.

          7.1.3 Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party enforceable against it in accordance with its terms and conditions.

          7.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder.

     7.2 Acknowledgment of Ribomic. Ribomic acknowledges that the licenses granted to
Ribomic hereunder are subject to certain limitations and restrictions set forth in the
Archemix-Gilead License Agreement and agrees that Ribomic shall comply with the terms of the
Archemix-Gilead License Agreement that Archemix is subject to thereunder.

     7.3  Additional Representations and Warranties.

          7.3.1 Additional Representations and Warranties of Archemix.

               (a) Authority. Archemix represents and warrants to Ribomic that Archemix Controls the
Licensed Patent Rights and Licensed Technology and has the right to grant the license granted to
Ribomic on the terms set forth herein.

               (b) No Litigation. Archemix represents and warrants to Ribomic that, as of the
Effective Date and with no further duty to update, to Archemix’s Knowledge, there is no pending
litigation against Archemix that seeks to invalidate or oppose any of the patents or patent
applications included in the Licensed Patent Rights.

               (c) Archemix-Gilead License Agreement. Archemix represents and warrants to Ribomic
that the Archemix-Gilead License Agreement as heretofore delivered by Archemix to Ribomic
represents the complete agreement and understanding between Gilead Sciences, Inc. and Archemix
relating to the Licensed Patent Rights which are the subject of the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

29

 

Archemix-Gilead License Agreement; the Archemix-Gilead License Agreement has not been
modified, supplemented or amended in any manner that would adversely affect the rights granted to
Ribomic under this Agreement, other than by amendments thereto provided to Ribomic prior to the
Effective Date; and the Archemix-Gilead License Agreement is in full force and effect and Archemix
is in compliance in all material respects with its obligations thereunder.

               (d) No Infringement. Archemix represents and warrants to Ribomic that to its
Knowledge, there is no litigation pending or threatened that alleges that (i) the practice of the
SELEX Process and/or the use of SELEX Technology as contemplated by this Agreement infringes the
Patent Rights of any Third Party, (ii) the Licensed Patent Rights are invalid or unenforceable; or
(iii) the use of the Licensed Patent Rights or Licensed Technology as contemplated by this
Agreement infringes the Patent Rights of any Third Party.

          7.3.2 Additional Representations and Warranties of Ribomic.

               (a) Authority. Ribomic represents and warrants to Archemix that Ribomic has the right
to grant the Archemix License granted to Archemix on the terms set forth herein.

               (b) No Litigation. Ribomic represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update (except as otherwise stated), there is no pending
litigation against Ribomic or any Affiliate of Ribomic that seeks to invalidate or oppose any of
the patents or patent applications included in the Ribomic SELEX Patent Rights.

               (c) No Conflict. Ribomic represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update, it is not researching, developing or
commercializing Aptamers that bind to a Target other than Aptamers that bind to the Program Target.

8. INDEMNIFICATION AND INSURANCE

     8.1 Indemnification of Archemix by Ribomic. Ribomic shall indemnify, defend and hold
harmless Archemix, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “Archemix Indemnitees”), against any
liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of
litigation) incurred by or imposed upon the Archemix Indemnitees, or any one of them, as a direct
result of claims, suits, actions or demands by Third Parties (collectively, the “Claims”)
arising out of (a) the research, development, testing, production, manufacture, supply, promotion,
import, sale or use by any Person of any Licensed Product (or any component thereof) manufactured
or sold by Ribomic or any of its Affiliates or Sublicensees or (b) the gross negligence or willful
misconduct of Ribomic or any of its Affiliates or Sublicensees.

     8.2 Conditions to Indemnification. An Archemix Indemnitee seeking recovery under this
Article 8 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of such
Claim to the indemnifying party (the “Indemnifying Party”) and provided that the
Indemnifying Party is not contesting its obligation under this Article 8, shall permit the
Indemnifying Party to control any litigation relating to such Claim and the disposition of such
Claim (including without limitation any settlement thereof); provided, that, the Indemnifying Party
shall not settle or otherwise resolve such Claim without the prior written consent of such

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

30

 

Indemnified Party, which consent shall not be unreasonably withheld, conditioned or delayed,
unless such settlement includes a full release of the Indemnified Party, in which case the
indemnifying Party may settle or otherwise resolve such Claim without the prior written consent of
such Indemnified Party. Each Indemnified Party shall cooperate with the Indemnifying Party in its
defense of any such Claim in all reasonable respects and shall have the right to be present in
person or through counsel at all legal proceedings with respect to such Claim.

     8.3 Indemnification of Gilead and UTC by Ribomic. If and solely to the extent, legally
required by the Archemix-Gilead License Agreement, Ribomic shall indemnify, defend and hold
harmless Gilead, its Affiliates and UTC and any of their respective directors, officers, employees
and agents (each, a “Gilead Indemnitee”), from and against any losses that are incurred by
a Gilead Indemnitee as a result of any Claims, to the extent such Claims arise out of the
possession, research, development, manufacture, use, offer for sale, sale or other
commercialization, distribution, administration, storage or transport, by Ribomic or its Affiliates
or Sublicensees of (a) any Aptamers or Licensed Products, or (b) any other products, services or
activities developed by Ribomic relating to the Licensed Patent Rights, including any Licensed
Products or Aptamers.

     8.4 Warranty Disclaimer. NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY
TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. NEITHER PARTY MAKES ANY
WARRANTIES AS TO THE VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS LICENSED BY SUCH PARTY TO THE
OTHER PARTY.

     8.5 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT,
EXCEPT WITH RESPECT TO RIBOMIC’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8.1 AND/OR 8.3, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST
REVENUES, OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER
ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

     8.6 Insurance. Ribomic will, at Ribomic’s expense, obtain and maintain in full force
and effect insurance with respect to the Development (to the extent it is related to the clinical
studies) and commercialization of Licensed Products in such amount as Japan-based biopharmaceutical
companies customarily maintain with respect to the clinical development and commercialization of
similar products. If Licensed Products are subject to clinical studies, then such insurance policy
or policies shall name Archemix as an additional named insured, shall be non-cancelable except upon
[***] days prior written notice to Archemix, and shall provide that as to any loss covered thereby
and also by any policies obtained by Archemix itself, Ribomic’s policies shall provide primary
coverage for Archemix and Archemix’ policies shall be considered excess coverage for Archemix.
Ribomic will forthwith after the obtaining of such

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

31

 

insurance required by this Section 8.6, obtain and deliver to Archemix certificates of and
copies of, and at all times thereafter deliver without further demand replacement certificates and
copies of, all such insurance policies that are in force and effect.

9. TERM AND TERMINATION

     9.1 Term; Expiration. The term of this Agreement (the “Term”) shall commence
on the Effective Date and continue, unless earlier terminated as provided herein, until such time
as all Royalty Terms for all Licensed Products have ended. Upon expiration (but not upon
termination prior to the expiration) of the Royalty Term applicable to a Licensed Product in a
country, Ribomic’s rights and licenses hereunder with respect to such Licensed Product in such
country shall become fully paid-up, non-royalty bearing, non-exclusive, perpetual rights and
licenses.

     9.2 Termination.

          9.2.1 Unilateral Right to Terminate. Ribomic shall have the right to terminate this
Agreement, for any reason, upon (a) at least ninety (90) days’ prior written notice to Archemix,
such notice to state the date following the date of receipt of such notice by Archemix upon which
termination is to be effective, and (b) the payment by Ribomic of all amounts due to Archemix
through such termination effective date.

          9.2.2 Termination for Challenge. In the event Ribomic, its Affiliates and/or
Sublicensees initiates a Challenge or assists a Third Party in initiating a Challenge, Archemix
shall have the right to terminate this Agreement, effective immediately upon written notice to
Ribomic.

          9.2.3 Termination for Breach. Except as set forth herein, either Party may terminate
this Agreement, effective immediately upon written notice to the other Party, for a material breach
by the other Party of this Agreement that, if curable, remains uncured for [***] days ([***] days
in the event that the breach is a failure of a Party to make any payment required hereunder) after
the non-breaching Party first gives written notice to the other Party of such breach and its intent
to terminate this Agreement if such breach is not cured.

          9.2.4 Termination for Insolvency. Each Party shall give the other Party reasonable
prior notice of the filing with respect to itself of any voluntary petition, and prompt notice of
the filing with respect to itself of any involuntary petition, under any bankruptcy laws. In the
event that either Party: (a) files for protection under bankruptcy laws; (b) makes an assignment of
all or substantially all of its assets for the benefit of creditors; (c) appoints or suffers
appointment of a receiver or trustee over all or substantially all of its assets; and (d) files a
petition under any bankruptcy or insolvency act or has any such petition filed against it which is
not discharged within [***] days of the filing thereof (each of (a)-(d), a “Bankruptcy
Action”), then the other Party may terminate this Agreement effective immediately upon written
notice to such Party. All rights and licenses granted under or pursuant to this Agreement are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
Code. Further, upon filing such protection or petition by Archemix, Archemix shall, without any
delay,

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

32

 

perform all necessary procedures under any then-applicable laws including, but not limited to,
Section 365(n) of the United States Bankruptcy Code, to protect all rights and licenses granted to
Ribomic under Section 2.1.1 hereof in order for retaining and defending such rights and license.
Notwithstanding any provision contained in this Agreement to the contrary, if any Bankruptcy Action
takes place with respect to Archemix, and the trustee in bankruptcy of Archemix, or Archemix as a
debtor-in-possession, properly elects to reject this Agreement, Ribomic may, pursuant to Section
365(n) of the Bankruptcy Code, retain and enforce any and all rights hereunder granted to Ribomic
to the maximum extent permissible by law. All rights, powers and remedies of Ribomic, as a
licensee hereunder, provided herein are in addition to and not in substitution for any and all
other rights, powers and remedies now or hereafter existing at law or in equity (including, without
limitation, the Bankruptcy Code) in the event of the commencement of a Bankruptcy Action with
respect to Archemix. Ribomic, in addition to the rights, powers and remedies expressly provided
herein, shall be entitled to exercise all other such rights and powers and resort to all other such
remedies as may now or hereafter exist at law or in equity (including the Bankruptcy Code) in such
event.

     9.3 Consequences of Termination of Agreement. In the event of the termination of this
Agreement pursuant to this Article 9, the following provisions shall apply:

          9.3.1 If this Agreement is terminated by Ribomic pursuant to Section 9.2.1 or by Archemix
pursuant to Sections 9.2.2, 9.2.3 or 9.2.4:

               (a) all licenses granted by Archemix to Ribomic under this Agreement shall immediately
terminate and Archemix shall have no further obligations under Section 2.3.1(a);

               (b) all licenses granted by Ribomic to Archemix prior to the termination of this Agreement
hereunder shall continue and survive in full force and effect;

               (c) Ribomic shall promptly return all Confidential Information of Archemix; provided, that
Ribomic may retain one (1) copy of Confidential Information of Archemix in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder;

               (d) each Sublicensee of Ribomic shall be considered a direct licensee of Archemix under this
Agreement; provided, that, (i) such Sublicensee is then in compliance with all terms and conditions
of its sublicense, (ii) all accrued payment obligations of such Sublicensee to Ribomic under the
Sublicense Agreement have been paid, and (iii) such Sublicensee agrees in writing to assume all
applicable obligations of Ribomic under this Agreement arising thereafter to the extent of the
scope of the sublicense;

               (e) upon request of Archemix, the Parties shall negotiate in good faith the terms of a
transition plan which shall provide for the terms pursuant to which Ribomic shall (i) transfer to
Archemix all of its right, title and interest in all regulatory filings and Regulatory Approvals
then in its name applicable to Licensed Products, if any, and all material aspects of Confidential
Information Controlled by it as of the date of termination relating to such regulatory filings and
Regulatory Approvals; (ii) notify the applicable regulatory authorities and take any other action
reasonably necessary to effect such transfer; (iii) provide Archemix with copies of all
correspondence between Ribomic and such regulatory authorities relating to such regulatory

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

33

 

filings and Regulatory Approvals; (iv) unless expressly prohibited by any regulatory
authority, transfer control to Archemix of all clinical trials of Licensed Products being conducted
as of the effective date of termination and continue to conduct such trials for up to six (6)
months to enable such transfer to be completed without interruption of any such trial; (v) assign
(or cause its Affiliates to assign) to Archemix all agreements with any Third Party with respect to
the conduct of clinical trials for Licensed Products including, without limitation, agreements with
contract research organizations, clinical sites and investigators, unless expressly prohibited by
any such agreement (in which case Ribomic shall cooperate with Archemix in all reasonable respects
to secure the consent of such Third Party to such assignment); (vi) provide Archemix with all
supplies of Licensed Products in the possession of Ribomic or any Affiliate or contractor of
Ribomic; (vii) provide Archemix with copies of all reports and data generated or obtained by
Ribomic or its Affiliates pursuant to this Agreement that relate to any Licensed Products that have
not previously been provided to Archemix; and (viii) supply Archemix with its requirements for
Licensed Products and intermediates for up to twenty-four (24) months following such termination at
a transfer price to be negotiated and included in such transition plan.

          9.3.2 If this Agreement is terminated by Ribomic pursuant to Sections 9.2.3 or 9.2.4, all
licenses granted by Archemix to Ribomic shall survive, subject to Ribomic’s continued payment of
all royalties, milestones, Sublicense Income Payments and other payments due and payable to
Archemix pursuant to Article 4; and Ribomic shall promptly return all Confidential Information of
Archemix that is not subject to a continuing license hereunder; provided, that Ribomic may retain
one (1) copy of each such Confidential Information of Archemix in it archives solely for the
purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.

          9.3.3 If Ribomic breaches any of its Specific Diligence Obligations pursuant to Section
3.1.2(b), with respect to a given Licensed Product then, in lieu of termination of this Agreement
pursuant to Section 9.3.1, Archemix shall have the right, in its sole discretion, upon ten (10)
days written notice to Ribomic, to (a) convert the exclusive license granted to Ribomic for each
such Licensed Product to non-exclusive, in which case Section 2.3.1(a) shall no longer apply to
such Licensed Product or (b) exercise its rights pursuant to Section 9.3.1 only on a Licensed
Product-by-Licensed Product and country-by-country basis.

     9.4 Remedies. Except as otherwise expressly set forth in this Agreement, the
termination provisions of this Article 9 are in addition to any other relief and remedies available
to either Party at law.

     9.5 Surviving Provisions. Notwithstanding any provision herein to the contrary, the
rights and obligations of the Parties set forth in Articles 5, 8 and 10 and Sections 4.6, 6.1, 6.2,
6.3, 6.4, 6.5.4, 9.1 and 9.3, as well as any rights or obligations otherwise accrued hereunder
(including any accrued payment obligations), shall survive the expiration or termination of the
Term.

10. DISPUTES

     10.1 Negotiation. The Parties recognize that a bona fide dispute as to certain
matters may from time to time arise during the Term that relates to either Party’s rights and/or
obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

34

 

written notice to the other Party, have such dispute referred to their respective senior
officials designated below or their successors or designees, for attempted resolution by good faith
negotiations within [***] days after such notice is received. Said designated senior officials are
as follows:

	 	 	 
	For Ribomic:
	 	[***]
	 
	 	 
	For Archemix:
	 	[***]

In the event the designated senior officials or their successors or designees are not able to
resolve such dispute within the [***] day period, either Party may invoke the provisions of
Section 10.2.

     10.2 Arbitration.

          10.2.1 Full Arbitration. Subject to Sections 10.1 and 10.2.3 below, any dispute,
controversy or claim initiated by either Party arising out of, resulting from or relating to this
Agreement or the performance by either Party of its obligations under this Agreement (excluding
actions under Article 9 and bona fide Third Party actions or proceedings filed or instituted in an
action or proceeding by a Third Party against a Party) (a “Dispute”), whether before or
after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a
Party shall decide to institute arbitration proceedings, it shall give written notice to that
effect to the other Party. Any such arbitration shall be conducted under the Commercial
Arbitration Rules of the American Arbitration Association (the “AAA”) by a panel of three
arbitrators appointed in accordance with such rules. Any such arbitration shall be held in Boston,
Massachusetts if such arbitration is demanded by Ribomic and in Honolulu, Hawaii if such
arbitration is demanded by Archemix. The method and manner of discovery in any such arbitration
proceeding shall be governed by the laws of the Commonwealth of Massachusetts. The arbitrator
shall have the authority to grant injunctions and/or specific performance and to allocate between
the Parties the costs of arbitration in such equitable manner as they determine. Judgment upon the
award so rendered may be entered in any court having jurisdiction or application may be made to
such court for judicial acceptance of any award and an order of enforcement, as the case may be.
In no event shall a demand for arbitration be made after the date when institution of a legal or
equitable proceeding based upon such claim, dispute or other matter in question would be barred by
the applicable statute of limitations. Notwithstanding the foregoing, either Party shall have the
right, without waiving any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional
relief that is necessary or desirable to protect the rights or property of such Party, pending the
selection of the arbitrator hereunder or pending the arbitrators’ determination of any dispute,
controversy or claim hereunder.

          10.2.2 Accelerated Arbitration. To the extent a Dispute submitted to arbitration by a
Party under Section 10.2.1 is claimed, by either Party, to involve matters covered by Sections
1.44, 1.70, 3.6, 3,7 or 4.2.5, the following procedures shall apply:

               (a) The Parties shall mutually select a single independent, conflict-free arbitrator (the
“Expert”), who shall have sufficient scientific background and financial experience to
resolve the Dispute. If the Parties are unable to reach agreement on the selection of an Expert

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

35

 

within [***] business days after submission to arbitration, then either or both Parties shall
immediately request that the AAA select an independent and impartial arbitrator with the requisite
scientific background, experience and expertise. The place of arbitration shall be Boston,
Massachusetts.

               (b) Each Party shall prepare and submit a written summary of such Party’s position and any
relevant evidence in support thereof to the Expert within [***] days of the selection of the
Expert. Upon receipt of such summaries from each Party, the Expert shall provide copies of the
same to the other Party. Within [***] days of the delivery of such summaries by the Expert, each
Party shall submit a written rebuttal of the other Party’s summary and may also amend and re-submit
its original summary. Oral presentations shall not be permitted unless otherwise requested by the
Expert. The Expert shall make a final decision with respect to the Dispute within [***] days
following receipt of the last of such rebuttal statements submitted by the Parties. Each Party
shall bear its own costs and expenses and attorneys’ fees, and the Party that does not prevail in
the arbitration proceeding shall pay the Expert’s fees and any administrative fees of arbitration.

          10.2.3 Litigation; Venue; Jurisdiction. Each of the Parties hereto hereby (a)
irrevocably and unconditionally agrees that any action or proceeding in respect of any claim
arising out of or related to this Agreement or the transactions contained in or contemplated by
this Agreement that is not a Dispute, whether in tort or contract or at law or in equity, shall be
brought by such Party exclusively in the state and federal courts of the State of New York (the
“Chosen Courts”); (b) irrevocably submits to the exclusive jurisdiction of the Chosen
Courts; (c) waives any objection to laying of venue in any such action or proceeding in the Chosen
Courts; (d) waives any objection that the Chosen Courts are an inconvenient forum or do not have
jurisdiction over any Party hereto; (e) agrees that service of process upon such Party in any such
action or proceeding shall be effective if notice is given in accordance with this Agreement; and
(f) agrees that a final judgment in any such action or proceeding shall be conclusive and may be
enforced by suit on the judgment or in any other manner provided by Applicable Laws or at equity.

11. MISCELLANEOUS

     11.1 Notification. All notices, requests and other communications hereunder shall be
in writing, shall be addressed to the receiving Party’s address set forth below or to such other
address as a Party may designate by notice hereunder, and shall be either (a) delivered by hand,
(b) made by facsimile transmission, (c) sent by private courier service providing evidence of
receipt or (d) sent by registered or certified mail, return receipt requested, postage prepaid.
The addresses and other contact information for the parties are as follows:

	 	 	 
	If to Ribomic:

	 	If to Archemix:
	 
	Ribomic, Inc.

	 	Archemix Corp.
	3-16-13 Shirokanedai Usui-Building

	 	300 Third Street
	Minato-Ku

	 	Cambridge, MA 02142
	Tokyo 108-007 Japan

	 	Tel: (617) 621-7700
	Tel: (03) 3440-3303

	 	Fax: (617) 621-9300
	Fax: (03) 3440-3729

	 	Attention: Chief Executive Officer

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

36

 

	 	 	 
	Attention: President

	 	Attention: Legal Department
	 
	 	 
	Attention: Legal Department

	 	With a copy to:
	 
	 	 
	 

	 	Mintz Levin Cohn Ferris Glovsky
and Popeo, P.C.
	 

	 	One Financial Center
	 

	 	Boston, MA 02110
	 

	 	Tel: (617) 542-6000
	 

	 	Fax: (617) 542-2241
	 

	 	Attn: John J. Cheney, Esq.

     All notices, requests and other communications hereunder shall be deemed to have been given
either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of
such Party set forth above, (ii) if made by facsimile transmission, at the time that confirmation
of receipt thereof has been received by the Party delivering such notice, (iii) if sent by private
courier, on the day such notice is delivered to the recipient or (iv) if sent by registered or
certified mail, on the fifth (5th) business day following the day such mailing is made.

     11.2 Governing Law. This Agreement will be construed, interpreted and applied in
accordance with the laws of the State of New York (excluding its body of law controlling conflicts
of law).

     11.3 English Language. All data, results and information that is in a language other
than English and that is provided by either Party to the other Party and/or to the DC under this
Agreement shall be provided both in its original format, without translation, and in an English
translation within [***] business days except for a Sublicense Agreement, if any, whose translation
shall be provided with [***] business days (which translation shall be made at the providing
Party’s sole cost and expense).

     11.4 Limitations. Except as expressly set forth in this Agreement, neither Party
grants to the other Party any right or license to any of its intellectual property.

     11.5 Entire Agreement. This is the entire Agreement between the Parties with respect
to the subject matter hereof and supersedes all prior representations, understandings and
agreements between the Parties with respect to the subject matter hereof. No modification or
amendment shall be effective unless in writing with specific reference to this Agreement and signed
by the Parties.

     11.6 Waiver. The terms or conditions of this Agreement may be waived only by a
written instrument executed by the Party waiving compliance. The failure of either Party at any
time or times to require performance of any provision hereof shall in no manner affect its rights
at a later time to enforce the same. No waiver by either Party of any condition or term shall be
deemed as a continuing waiver of such condition or term or of another condition or term.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

37

 

     11.7 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form part of this Agreement.

     11.8 Assignment. Neither this Agreement nor any right or obligation hereunder may be
assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior
express written consent of the other; provided, that, either Party may, without the written consent
of the other, assign this Agreement and its rights and delegate its obligations hereunder to its
Affiliates or in connection with the transfer or sale of all or substantially all of such Party’s
assets or business to which this Agreement relates or in the event of its merger, consolidation,
change in control or similar transaction. Any permitted assignee shall assume all obligations of
its assignor under this Agreement. Any purported assignment in violation of this Section 11.8
shall be void. The terms and conditions of this Agreement shall be binding upon and inure to the
benefit of the permitted successors and assigns of the parties.

     11.9 Force Majeure. Neither Party shall be liable for failure of or delay in
performing obligations set forth in this Agreement, and neither shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes beyond the
reasonable control of such Party. In event of such force majeure, the Party affected thereby shall
use reasonable efforts to cure or overcome the same and resume performance of its obligations
hereunder.

     11.10 Construction. The Parties hereto acknowledge and agree that: (a) each Party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (b) the rule of construction to the effect that any ambiguities are
resolved against the drafting Party shall not be employed in the interpretation of this Agreement;
and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties
hereto and not in favor of or against any Party, regardless of which Party was generally
responsible for the preparation of this Agreement.

     11.11 Severability. If any provision(s) of this Agreement are or become invalid, are
ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current
applicable law from time to time in effect during the Term hereof, it is the intention of the
Parties that the remainder of this Agreement shall not be affected thereby; provided, that, a
Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and
agree to renegotiate any such term, covenant or application thereof in good faith in order to
provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or
the application thereof that is invalid, illegal or unenforceable, it being the intent of the
Parties that the basic purposes of this Agreement are to be effectuated.

     11.12 Status. Nothing in this Agreement is intended or shall be deemed to constitute
a partner, agency, employer-employee or joint venture relationship between the Parties.

     11.13 Further Assurances. Each Party agrees to execute, acknowledge and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

38

 

     11.14 Counterparts. This Agreement may be executed simultaneously in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

[Remainder of page intentionally left blank.]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

39

 

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective
duly authorized representative in 

two (2) originals.

	 	 	 	 	 	 	 	 	 
	RIBOMIC, INC.	 	 	 	ARCHEMIX CORP.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Michi Nishiyawa	 	 	 	By:	 	/s/ John A. Harre
	 

	 	 
	 	 	 	 	 	 
	Name:

	 	Michi Nishiyawa	 	 	 	Name:	 	John A. Harre
	 

	 	 
	 	 	 	 	 	 
	Title:

	 	President and CEO	 	 	 	Title:	 	Vice President I.P. and Legal
Affairs
	 

	 	 
	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

40

 

Schedule 1

Chemical Composition of Program Target

[***]

Chemical compositions comprising an amino acid sequence described above in which several amino
acids may be substituted, deleted, or inserted (but in no case containing less that [***]% identity
to the specified sequence).

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

Schedule 1-1

 

Schedule 2

Specific Diligence Obligations

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Milestone	 	Year
	[***]
	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 
	 
	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	 	 
	 
	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	[***]	 
	 
	 	 	[***]	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

Schedule 2-1

 

Schedule 3

Required Jurisdictions

[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

Schedule 3-1

 

Exhibit A

Licensed Patent Rights

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

Exhibit A-1

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Mintz Ref.	 	 	 	Appl.	 	 	 	 
	No.	 	Status	 	Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

Exhibit B

Ribomic SELEX Patent Rights

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Appln No.	 	 	 	 	 	 	 	 	 	 
	COUNTRY	 	(Publn No)	 	Patent No.	 	Title	 	Status	 	File	 	Issue
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

Exhibit B-1

 

Exhibit C

Development Plan

[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

AMENDMENT NO. 1 TO THE

EXCLUSIVE LICENSE AGREEMENT

     This Amendment No. 1 (this “Amendment”) to the Exclusive License Agreement dated as of
December 10, 2007 (the “License Agreement”) by and between Archemix Corp., a Delaware corporation
with offices at 300 Third Street, Cambridge, MA 02142 (“Archemix”), and Ribomic, Inc., a
corporation organized under the laws of Japan with offices at Shirokanedai Usui Building, 3-16-13
Shirokanedai, Minato-ku, Tokyo 108-0071 Japan (“Ribomic”),
is entered into as of June 11, 2008 (the
“Amendment Effective Date”) by and between Archemix and Ribomic. Capitalized terms used but not
otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement.

     WHEREAS, the Parties entered into the License Agreement pursuant to which Archemix granted
Ribomic an exclusive license under certain patent and proprietary technology Controlled by Archemix
to identify Aptamers against a specified Program Target, and to develop and commercialize Licensed
Products derived from such Aptamers for use in the Field; and

     WHEREAS, the Parties hereto desire to amend the License Agreement as set forth herein and to
set forth certain additional terms applicable to the License Agreement, as so amended.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as
follows:

          1. Amendments to License Agreement.

          (a) Section 1.7 of the License Agreement is hereby deleted in its entirety and the following
inserted in lieu thereof:

          11.15 “1.7 “Aptamer” means (a) any naturally or non-naturally occurring
oligonucleotide identified through the SELEX Process that binds with high
specificity and affinity to a Target, and (b) any oligonucleotide Derived from an
oligonucleotide of clause (a) that has such high specificity and affinity to a
Target, but excluding in both (a) and (b) Spiegelmers.”

          (b) Section 1.25 of the License Agreement is hereby deleted in its entirety and the following
inserted in lieu thereof:

          11.16 “1.25 “Existing License Agreements”means, collectively,
(a) the
Non-Exclusive IgG Antibody Purification License Agreement dated as of October 31,
2006, by and between the Parties; (b) the Research License and Option Agreement
dated as of June 11, 2008, by and between the Parties; and (c) any License
Agreement entered into by the Parties pursuant to the terms of the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

Research License and Option Agreement.”

               (c) Section 1.26 of the License Agreement is hereby deleted in its entirety and the
following
inserted in lieu thereof:

“1.26 “Field”means the prevention, treatment or cure of any Indication in animals
and humans, but excluding, without limitation, Diagnostic Products, In Vivo Imaging
Applications, all non-therapeutic uses and Spiegelmers.”

               (d) Section 1.40 of the License Agreement is hereby deleted in its entirety and the
following
inserted in lieu thereof:

          11.17 “1.40 “Licensed Patent Rights” means all Patent Rights Controlled
by Archemix or any of its Affiliates and listed on Exhibit A attached hereto
to the extent that they are (a) issued patents as of the Effective Date or (b)
pending patent applications as of the Effective Date that will expire on or before
September 23, 2014 as well as any patent issuing on said pending patent applications
and, in any case, are necessary for Ribomic to practice the licenses granted to it
hereunder. It is understood that any pending patent applications listed on
Exhibit A that will expire after September 23, 2014 as well as any patent
issuing thereon shall become part of the Licensed Patent Rights only by mutual
agreement of the Parties.”

               (e) Section 1.50 of the License Agreement is hereby deleted in its entirety and the
following
inserted in lieu thereof:

          11.18 “1.50 “Permitted Ribomic Activities”means, on a
country-by-country and Valid Claim-by-Valid Claim basis, any activity conducted by
Ribomic or any of its Affiliates or Sublicensees (a) involving the discovery,
research, development and commercialization of aptamers in a country for use in the
Field against any Target other than the Program Target at any time on and after the
expiration of the last to expire applicable Valid Claim of the Licensed Patent
Rights in such country or (b) pursuant to the terms of any of the Existing License
Agreements, for so long as such Existing License Agreement continues in full force
and effect.”

               (f) The following new definitions are hereby added to Section 1 of the License Agreement
and
the remaining sections of Section 1 and references thereto are hereby renumbered accordingly:

“1.68 “Spiegelmer” means an oligonucleotide consisting of at least [***] percent
([***]%) [***], including any structural variations and modifications, derivatives,
homologs, analogs and/or mimetics to the [***] (other than [***]), identified through the
use of the SELEX Process.”

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

               (g) The first sentence of Section 2.1.1(b) of the License Agreement is hereby deleted in
its
entirety and the following inserted in lieu thereof:

     “(b) Negative Covenants. Ribomic is not granted the right to, and
hereby covenants and agrees that neither it nor its Affiliates will (i) use the
SELEX Process or SELEX Technology (A) on any Target that is not the Program Target
and (B) except for the purpose of identifying or modifying Program Aptamers and/or
for the conduct by Ribomic of Permitted Ribomic Activities as expressly permitted
under this Agreement, (ii) research, develop, make, have made, use, have used, sell,
offer for sale, have sold, distribute for sale, import, have imported, export or
have exported Diagnostics or Spiegelmers or (iii) perform any research or
development on Program Aptamers for any use outside of the Field.”

          (h) Section 4.3.4 of the License Agreement is hereby deleted in its entirety and the following
inserted in lieu thereof:

“4.3.4 Royalty and Milestone Reductions.

     11.19 (a) Third Party Non-Spiegelmer Products (Royalty Reduction). In
the event that a Third Party sells an aptamer product that is not a Third Party
Spiegelmer Product that binds to the Program Target (a “Third Party
Non-Spiegelmer Product”) in a country in which a Program Aptamer or Licensed
Product is then being sold by Ribomic and such Third Party Non-Spiegelmer Product is
not covered by a Valid Claim under the Licensed Patent Rights in such country, then,
during the period in which sales of the Third Party Non-Spiegelmer Product are equal
to at least [***] percent ([***]%) of Ribomic’s volume-based market share of the
Program Aptamer or Licensed Product in such country (as measured by prescriptions or
other similar information available in such country) all applicable royalties in
effect with respect to such Program Aptamer or Licensed Product in such country as
specified in Section 4.3.1 shall be reduced by [***] percent ([***]%).
Notwithstanding the foregoing, Ribomic’s obligation to pay royalties at the full
royalty rates shall be reinstated on the first day of the Calendar Quarter
immediately following the Calendar Quarter in which sales of such Third Party
Non-Spiegelmer Product account for less than [***] percent ([***]%) of Ribomic’s
volume-based market share in such country.

     11.20 (b) Third Party Spiegelmer Products (Royalty Reduction). In the
event that a Third Party sells a Spiegelmer that binds to the Program Target (a
“Third Party Spiegelmer Product”) in a country in which a Program Aptamer or
Licensed Product is then being sold by Ribomic then all applicable royalties in
effect with respect to such Program Aptamer or Licensed Product in such country as
specified in Section 4.3.1 shall be reduced by [***] percent ([***]%).
Notwithstanding the foregoing, Ribomic’s obligation to pay royalties at the full
royalty rates shall be reinstated on the first day of the Calendar Quarter
immediately following the Calendar Quarter in which sales of such Third Party
Spiegelmer Product cease in such country.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

     11.21 (c) Third Party Spiegelmer Product (Milestone Payment Reduction).
In the event that a Third Party initiates clinical trials of a Third Party
Spiegelmer Product in any country of the Defined Territory, then each applicable
Milestone payment payable after the [***] with respect to any Program Aptamer or
Licensed Product as specified in Section 4.2 hereof shall be reduced by [***]
percent ([***]%) to the extent such Third Party is developing and/or commercializing
the Third Party Spiegelmer Product in any country in the Defined Territory at the
time such Milestone payment becomes due and payable.”

          (i) Section 11.1 of the License Agreement is hereby deleted in its entirety and the following
inserted in lieu thereof:

11.22      “11.1 Notification. All notices, requests and other communications
hereunder shall be in writing, shall be addressed to the receiving
Party’s address set forth below or to such other address as a Party
may designate by notice hereunder, and shall be either (a) delivered
by hand, (b) made by facsimile transmission, (c) sent by private
courier service providing evidence of receipt or (d) sent by
registered or certified mail, return receipt requested, postage
prepaid. The addresses and other contact information for the
parties are as follows:

	 	 	 
	If to Ribomic:
	 	If to Archemix:
	 
	Ribomic, Inc.
	 	Archemix Corp.
	Shirokanedai Usui Building
	 	300 Third Street
	3-16-13 Shirokanedai
	 	Cambridge, MA  02142
	Minato-ku
	 	Tel:  (617) 621-7700
	Tokyo 108-0071 Japan
	 	Fax:  (617) 621-9300
	Tel: (03) 3440-3303
	 	Attention:  Chief Executive Officer
	Fax: (03) 3440-3729
	 	Attention:  Legal Department
	Attention: President
	 	 
	 
	 	 
	Attention: Legal Department
	 	 
	 
	 	 
	 
	 	With a copy to:
	 
	 	 
	 
	 	Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
	 
	 	One Financial Center
	 
	 	Boston, MA  02110
	 
	 	Tel:  (617) 542-6000
	 
	 	Fax:  (617) 542-2241
	 
	 	Attn:  John J. Cheney, Esq.

11.23      All notices, requests and other communications hereunder shall be deemed to have
been given either (i) if by hand, at the time of the delivery thereof to the receiving
Party at the address of such Party set forth above, (ii) if made by facsimile
transmission, at the time that confirmation of receipt thereof has been received by
the Party delivering such notice, (iii) if sent by private courier, on the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

day such notice is delivered to the recipient or (iv) if sent by registered or
certified mail, on the fifth (5th) business day following the day such
mailing is made.”

          (j) Exhibit A attached to the License Agreement is hereby deleted in its entirety and
replaced, in lieu thereof, by Exhibit A (dated May 19, 2008) attached hereto.

     2. Miscellaneous. The Parties hereby confirm and agree that, except as amended hereby,
the License Agreement remains in full force and effect and is a binding obligation of the Parties
hereto. This Amendment may be executed in counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly
authorized representatives.

	 	 	 	 	 	 	 
	 	 	ARCHEMIX CORP.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ John A. Harre	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	John A. Harre	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	Vice President I.P. and Legal
Affairs	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	RIBOMIC, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Michi Nishiyawa	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	Michi Nishiyawa	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	President and CEO	 	 
	 

	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

Exhibit A (dated May 19, 2008)

Licensed Patent Rights

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

 

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
 Commission pursuant to the Company’s application requesting confidential treatment under Rule 406
 of the Securities Act.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]